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SOMMARIO 
Considerato il ruolo essenziale che lo ione calcio riveste nella fisiologia di tutte le 
cellule, diversi meccanismi intervengono nel preciso controllo della sua 
concentrazione intracellulare ([Ca2+]i). Nel muscolo scheletrico in particolare, 
l’efficiente regolazione del Ca2+ citosolico è cruciale per garantire la corretta 
funzionalità del tessuto. Anomalie a carico dell’omeostasi del Ca2+ contribuiscono 
infatti all’eziologia di patologie muscolari quali la distrofia muscolare di Duchenne 
(DMD). Sebbene un’alterazione della [Ca2+]i sia stata più volte descritta in cellule 
muscolari distrofiche, i pathway coinvolti nel rilascio di Ca2+ ed il ruolo dei canali 
store-operati nei progenitori miogenici distrofici non sono noti. All’interno 
dell’eterogenea popolazione dei progenitori ematopoietici/endoteliali circolanti, 
abbiamo identificato una sottopopolazione di cellule CD133+ dotata di proprietà 
miogeniche. Il riscontro dell’espressione di CD20 sulla membrana di tali cellule 
rappresenta un’evidenza inattesa, trattandosi di un antigene tipicamente associato 
ai linfociti B. La precisa funzionalità biologica di CD20 non è nota, sebbene diverse 
osservazioni suggeriscano un suo coinvolgimento nel regolare la concentrazione 
intracellulare di calcio ([Ca2+]i). I dati presentati nella prima parte della tesi 
descrivono la differente attivazione di un pathway legato a CD20 in cellule 
staminali CD133+ normali e distrofiche, responsabile di un significativo incremento 
del calcio citosolico a carico delle cellule distrofiche. Nonostante CD20 possa 
influire sulla [Ca2+]i attraverso un pathway specifico, diversi studi hanno dimostrato 
la sua localizzazione nei domini di membrana denominati lipid raft, dove CD20 
sembra funzionare direttamente come canale Ca2+ store-operato. L’importanza 
dell’ingresso di Ca2+ store-operato (SOCE) nella fisiologia e nello sviluppo del 
muscolo scheletrico è stata riconosciuta solo di recente, e diversi interrogativi 
inerenti la modulazione del SOCE in questo tessuto rimangono aperti. Per tale 
motivo, unitamente alla comune origine mesodermica di sangue e muscolo, 
abbiamo ritenuto opportuno investigare il contributo di CD20 nella regolazione del 
calcio intracellulare in cellule muscolari. CD20 è risultato espresso nel muscolo 
scheletrico, mostrando una localizzazione di membrana in mioblasti e fibre 
muscolari. Inoltre l’inibizione di CD20 ha comportato la specifica compromissione 
del SOCE nella linea di mioblasti murini C2C12. Nel complesso le evidenze 
riportate hanno evidenziato l’alterazione di un pathway legato a CD20 in cellule 
staminali distrofiche, il cui ruolo nella patologia DMD può pertanto essere 
ipotizzato. I risultati prodotti dimostrano anche come la piena funzionalità di CD20 
sia necessaria affinché l’ingresso di Ca2+ store-operato possa avvenire in mioblasti 
C2C12, contribuendo ad ampliare la comprensione dei meccanismi che regolano il 
SOCE nel muscolo scheletrico. 
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ABSTRACT 
The calcium ion plays an essential role in the physiology of all living cells. 
Accordingly, multiple mechanisms contribute to the precise control of its 
intracellular concentration ([Ca2+]i). Particularly in skeletal muscle, the efficient 
regulation of cytosolic Ca2+ is crucial for tissue functionality and impairment of Ca2+ 
homeostasis has been shown to contribute to the etiology of muscular disorders 
such as Duchenne muscular dystrophy (DMD). Although the impairment of Ca2+ 
homeostasis affecting dystrophic muscular cells has been extensively reported, the 
pathways involved in calcium-release and the role of store-operated Ca2+ channels 
in dystrophic myogenic progenitors were not investigated before. Among the 
heterogeneous population of circulating hematopoietic and endothelial progenitors, 
we identified a subpopulation of CD133+ cells displaying myogenic properties. 
Interestingly, expression of the B-cell marker CD20 was observed in blood-derived 
CD133+ stem cells. Among the scarce available data about the biological role of 
the membrane protein CD20, there are some evidences of its involvement in the 
regulation of intracellular calcium concentration ([Ca2+]i). Here, we show that a 
CD20-related pathway leading to an increase of cytosolic calcium is differently 
activated in normal and dystrophic blood-derived CD133+ stem cells, supporting 
the assumption of a CD20-related calcium impairment affecting dystrophic cells. 
Although CD20 can modulate cytosolic calcium through a specific signaling 
pathway, other studies demonstrated its association with lipid raft domains of the 
plasma membrane, where it probably functions directly as a store-operated Ca2+ 
channel. Recent works indicated that store-operated Ca2+ entry (SOCE) plays a 
central role in skeletal muscle physiology and development, but there remain a 
number of unresolved issues relating to SOCE modulation in this tissue. That being 
so, and considering that blood and muscle share common mesodermic origins, we 
were prompted to investigate whether CD20 contributes to calcium handling in 
committed muscular cells. Expression of CD20 was observed in skeletal muscle, 
displaying a membrane localization in myoblasts and adult muscle fibers. 
Additionally, we showed that inhibition of CD20 resulted in specific impairment of 
SOCE in C2C12 myoblasts. Together, reported findings contributed to identify 
deregulated pathways affecting dystrophic stem cells and potentially involved in 
DMD pathology. Moreover, our results suggested that functional CD20 is required 
for SOCE to consistently occur in C2C12 myoblasts, providing a novel insight to 
improve the understanding of store-operated Ca2+ entry regulation in skeletal 
muscle. 
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INTRODUCTION 
1. Origin, structure and physiology of skeletal muscle 
Muscles can be categorized into three types based upon structure, function, and 
location in the body. The three types of muscle are skeletal, cardiac, and smooth 
muscle which have two common functions: (1) ensure movement and (2) produce 
force. In particular skeletal muscles also generate heat, thus participating to the 
thermoregulation of the body. Skeletal muscle is attached to the skeleton through 
tendons and thus it moves the body and its components. It appears striated under 
the microscope and is under voluntary control. Cardiac muscle is only located in 
the heart. It is also striated, but is not under voluntary control. Smooth muscle 
surrounds blood vessels and other passageways, regulates their size and propels 
material through body tubes. Smooth muscle is distributed throughout the body. It 
lacks striations and is involuntary. The respiratory and digestive tracts have layers 
of smooth muscle in their walls. Skeletal, cardiac and smooth muscle share 
common embryonic origins, being all derived from the middle germ layer: the 
mesoderm. Mesoderm lies between ectoderm and endoderm, the outermost and 
the innermost layer respectively. Together, they represent the first three tissue 
types to differentiate in an early stage of embryonic development, the gastrula, at 
approximately day sixteen, and from which all other more specialiazed tissues are 
later derived. Particularly, the epidermis and its derivatives, the nervous system 
and its sensory receptor cells derive from the ectoderm. The mesoderm develops 
into the connecitve tissues, bone, cartilage, dentin, cementum, all types of muscle, 
blood, endothelium of blood vessels, synovial membranes, serous membranes 
lining body cavities, the epithelium of the kidneys and urinary drainage system, the 
germinal epithelium of the gonads and the linings of the reproductive tracts. 
Endoderm develops into the epithelial linings of the gastrointestinal tract, the lungs, 
and associated structures (Table 1). A schematic representation of the events 
leading to the differentiation of the three primary embryonic germ layers is reported 
in Fig. 1. 
 
 
Table 1: Derivatives of the primary germ layers 
(Copyright 2004 Pearson Education, Inc.). 
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Figure 1 (part 1): Schematic representation of gastrulation in vetrebrates. A 
gastrula develops from a blastula by the inward migration of cells by a complex and 
coordinated series of cellular movements which occur at the end of the cleavage 
stage of development. (Copyright 2004 Pearson Education, Inc.). 
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Figure 1 (part 2): The cells begin to differentiate into the three primary embryonic 
germ layers, ectoderm and endoderm first, followed shortly thereafter by 
mesoderm (Copyright 2004 Pearson Education, Inc.). 
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1.1 Specification of skeletal muscle from paraxial mesoderm 
In vertebrate, skeletal muscle origins during embryonic development from somites, 
which are mesoderm paraxial masses, lateral to the neural tubes and the 
notochord [1]. Somites are divided into two components: the dermomyotome, 
which represents the dorsal part from which derm (comprising also endothelial and 
smooth muscle progenitors) and skeletal muscle origin, and the sclerotome, which 
is the ventral portion contributing to the formation of cartilage and bones of the 
spinal column and rib cage. The dermomyotome is subdivided in epiaxial, the inner 
part from which lumbar and vertebral muscles form, and ipoaxial, from which the 
remaining muscles origin (Fig. 2) [1].  
 
 
Figure 2: Representation of somitogenesis. Schematic representation of 
vertebrate somitogenesis as it occurs in the mouse embryo. Somites are formed 
and mature following a rostrocaudal gradient on either side of the axial structures. 
 
The progenitors of skeletal muscle are represented by the multi-potent stem cells 
which are localized in the hipoaxial dermomyotome and migrate after delamination  
from the dermamyotome towards developing limbs, tongue and diaphragm [2, 3]. 
The myogenic commitment is regulated by Wnts and sonic hedgehog (Shh) which 
are derived from axial structures [4] and activate either Paired Box (Pax) genes or 
directly MRFs (Myogenic Regulation Factors). Otherwise delamination to form 
migratory myoblasts is controlled by HGF (Hepatocyte Growth Factor) which is 
secreted by mesoderm cells and activating c-met, a tyrosin/kinasic receptor, 
expressed by lateral dermo-myotomal myoblasts, but not somites [5]. The 
expression of c-met is necessary for migration of muscle progenitors cells and is 
transcriptionally controlled by Pax3 a Pair Ruled gene that, together with the 
paralogue Pax7 (mainly expressed from the foetal stage onwards) regulate 
myogenic progenitors [6-8]. Transient activation of Notch, which is a factor 
produced by many cell types surrounding myoblasts, is necessary to promote 
proliferation and prevent premature differentiation of myoblasts. The differentiation 
of myogenic progenitors is a dynamic process controlled by the MRF genes, which 
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determine the formation of the myotome. Cells forming the myotome do not 
express Pax3 and Pax7 and directly activate MRFs (Myf5 and MyoD, and later 
MRF4 and Myogenin) differentiating into mononucleated, differentiated myocytes, 
that likely form a scaffold for the primitive epiaxial myofibers (Fig. 3A) [9-12]. MRFs 
belong to the family of bHLH (basic helix-loop-helix) proteins and include Myf5 
(Myogenic factor 5), MyoD (Myoblast determination protein), MRF4 (Muscle 
specific regulatory factor 4) and Myog (myogenin) [13]. Myf5 and MyoD are the first 
factors to be induced during differentiation. Importantly, the absence of one of 
these factors does not preclude muscle-lineage differentiation. It was previously 
demonstrated that these factors are induced by Pax3 and Pax7, except than in the 
myotome, in all subsequent generations of myoblasts (embryonic, foetal and 
satellite cells [14-17]. Myog is a downstream target of MyoD and regulated the 
transition of myoblasts to myocytes and myotubes by direct transcriptional 
activation of structural muscle genes. MRF4 is essential in the final stages of 
differentiation [18, 19]. The analogies between the mechanisms regulating 
myogenesis and those that activates satellite cells, strongly suggest that 
regeneration of adult muscles somehow recapitulates embryonic development. 
Satellite cells (SCs) are an heterogeneous population of stem cells necessary for 
the growth, maintenance and regeneration of skeletal muscle [13, 20]. They are 
localized in niches between the basal lamina and the sarcolemma, and represent 
approximately 90% of post-natal muscle progenitors, which are already committed 
cells that express Pax7 and, after activation, Myf5. The remaining 10% is 
constituted by stem cells positive for Pax7 and negative for Myf5 [21]. During 
muscle regeneration, quiescent SCs activate and proliferate through a self-renewal 
process which includes either asymmetric division or stochastic differentiation. 
Symmetric expansion is particularly induced in the latest phases of muscle 
regeneration through the action of Wnt7a. Much as it happens to muscle 
progenitors during embryonic myogenesis, committed SCs positive for Pax7 and 
Myf5 initiate to express MyoD and become myoblasts. They proliferate and 
differentiate into myotubes by repressing Pax7 and activating MRF4. Newly formed 
myocytes form new myotubes or fuse with damaged fibers (Fig. 3B). However 
during this expansion phase, asymmetric divisions occur that generate a 
Pax7+/MyoD- cells that return to quiescence and are required to maintain the “pool” 
of stem cells for subsequent regeneration cycles [22]. 
 
 6 
 
 
Figure 3: (A) Representation of myogenesis. (B) Representation of SCs 
differentation. 
1.2 Skeletal muscle ultra-structure 
Every skeletal muscle acts like an integrated unit of several muscle fibers (also 
called myofibers). The unit responsible for contraction is in fact made by a group of 
fibers and the motor neurons that innervate them. Inside a muscle, myofibers are 
oriented with the longitudinal axis parallel and are kept attached one to another by 
connective tissue called endomysium (the muscle fiber basal lamina) and 
perimysium, a ticker layer of connective that groups together several myofibers 
(Fig. 4). Between the bundles of fibers there are collagen, elastic fibers, nerves and 
blood vessels. Muscle is contained inside a connective sheath called epimysium. 
Every muscle fiber is a long cylindrical cell with up to hundreds of nuclei localized 
superficially. They are the biggest cell type since they originate from the fusion of 
several embryonic cells. The membrane of the muscle fiber is called sarcolemma 
and the cytoplasm is termed sarcoplasm. The muscle fibers are characterized by a 
small portion of cytosol since the principal intracellular structures are the 
myofibrilles, which are bundles of contractile and elastic proteins responsible of 
contraction. The myofibers also contain an extended sarcoplasmatic reticulum 
(SR), which is a modified form of the endoplasmatic reticulum (ER) that envelope 
myofibrilles. The role of SR is to concentrate and retain calcium ions. Strictly 
associated to SR is a branched network of the transversal tubules, known as T 
tubules. The membrane of T tubules is continuous with the surface of muscle 
fibers, so that the lumen of T tubules is in communication with the extracellular 
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liquid. They allow action potential, originating on the membrane at the level of the 
neuromuscular junction, to be rapidly transmitted inside the fiber. Without them, in 
fact, the action potential would reach the centre of the fibers just by the diffusion of 
positive charges into the sarcoplasm. Importantly, the sarcoplasm around the 
myofibrilles contains a lot of glycogen granules and mitochondria which provide 
energy during contraction. Glycogen is the molecule used by animals to store 
glucose and mitochondria provide ATP during muscle contraction.  
 
 
Figure 4: Skeletal muscle ultra-structure and sarcomere structure 
1.3 Skeletal muscle contraction 
Every muscle fiber results from the assembly of thousands myofibrils, which are 
composed by different type of proteins: the contractile proteins myosin and actin; 
the regulatory proteins tropomyosins and troponins and many proteins forming the 
scaffold of the sarcomere, including the accessory giant proteins titin and nebulin. 
The myosin (MyHCs) constitutes the thick filaments of myofibrils and different 
muscle types are characterized by the composition of different myosin isoforms. 
Every myosin is composed by two heavy chains that intertwine to form a long spiral 
tail with two globular heads, and four light chains (Fig. 5). The heavy and light 
chains of several myosins intercalate in order to form a tubular rigid structure with 
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the elastic heads on the extremity that protrude and function as an hinge during 
muscle contraction (Fig. 5). Actin is a globular protein (G-actin) that forms the thin 
filaments of the myofibril. Several molecules of actin polymerize to form long 
filaments (F-actin) and two polymers of F-actin wrap one on another to form the 
thin filaments (Fig. 5 and 6). The thick and thin filaments are parallel one to another 
and are interconnected by transversal bridges represented by the heads of the 
myosins. Every G-actin as a single binding site on one head of the myosin. The 
disposal of thin and thick filaments in the myofibril gives origin to the alternation of 
light and darks band from which derives the term “striated muscle”. Every single 
repetition of band constitutes the sarcomere which is composed by (Fig. 6): 
- Z disks: these are zigzag protein structures to which thin filaments attach. A 
sarcomere is made up of two Z disks e the thin filaments attached to them. 
- I bands: these are the light bands and are composed by thin filaments. 
- A bands: these are the dark bands and covers the entire length of one thick 
filament. At the extremity of this band, the thin and thick filaments overlap while the 
centre is occupied only by the thick filaments. 
- H zone: this is the central region of A band. 
- M line: this band represents the site of attachment of thick filaments. It is the 
equivalent of Z disk for the thin filaments.  
The titin is a giant elastic protein which extends from a Z disk to the next M line. It 
has two functions: (1) it stabilizes the position of contractile filaments; (2) its 
elasticity aloud the muscle to maintain is length constant after contraction. Titin 
collaborates with the giant non-elastic protein nebulina that guarantees the 
alignment of actin filaments in the sarcomere. 
 
 
Figure 5: The contracting and regulating proteins of skeletal muscle 
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Figure 6: The structure of sarcomere 
 
The contraction of muscle fibers generates force necessary to produce movement 
or to resist a load. The strength developed by muscular contraction is defined 
tension. In the past centuries, scientists believed that during contraction, the 
muscle shortens since it is made of molecules that shorten when active and 
elongate at rest. However, in 1954 Andrew Huxley and Rolf Niedeigerke 
discovered that the length of A bands does not change during muscle contraction 
and proposed a different model to explain muscle contraction: the theory of the 
scroll of the filaments. In this model the length of the filaments does not vary but 
they simply overlap slipping one on another. This model includes either that the 
muscle shorten during contraction in order to make a movement either that the 
muscle does not shorten when it generates a tension without making a movement. 
According to this theory, when the myofibril is at rest, thin and thick filaments 
overlap for a small region in the extremities. When the muscle contracts, the actin 
and myosin filaments slip one onto another so that the sarcomere shortens: the 
extremities of 2 Z disks get closer, the I band and H zone disappear while the 
length of the A band remains constant. The strength that drives the actin filaments 
is the movement of the transversal bridges of myosin that link actin and myosin. 
Myosin is a motor protein that converts the binding of ATP into mechanical energy: 
every molecule of myosin hydrolyses ATP into ADP and inorganic phosphate; the 
energy released modifies the angle between the head of myosin and the axis of its 
filament. In this model, the actin filament functions as a guide for the heads of 
myosin and has a single binding site for one myosin-head and single binding site 
for a molecule of ATP. During every rotation of the myosin-head, myosin releases 
actin, retracts and binds to a new molecule of actin, in order to start a new cycle of 
contraction.  
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In conclusion the contraction-cycle can be summarized as follows (Fig. 7): 
(1) It starts with the myosin-head bound to a molecule of G-actin. In this phase 
there is no ATP associated to the myosin.  
(2) A molecule of ATP binds to the myosin-head and the myosin detaches 
from actin. 
(3) ATP is hydrolyzed in ADP and inorganic phosphate that remain associated 
to myosin. 
(4) Head-myosin rotates and bind to a new molecule of G-actin. 
(5) The rotation of the head-myosin starts when the inorganic phosphate 
dissociates.  
When the myosin-head moves, it drives the F-actin to the centre of the sarcomere. 
Myosin releases ADP and returns to be strictly linked to actin. The cycle is ready to 
start again. 
 
 
Figure 7: The contraction-cycle 
 
The thin filaments of actin are associated to two regulatory proteins that avoid the 
myosin-head to complete their cycle. The tropomyosin is an elongated polymer that 
wrap over the F-actin, blocking part of the site for the myosin on each molecule of 
actin (Fig. 7). In order to perform the contraction, tropomyosin needs to completely 
release the binding site for myosin allowing the rotation of the myosin-heads. The 
capacity of the tropomyosin to release this binding site depends on the regulatory 
protein troponin, a complex of three proteins associated to tropomyosin (troponin I, 
C and T). When a contraction starts, troponin C reversible binds to Ca2+. This 
binding makes tropomyosin to retract, freeing the binding sites of myosin. In order 
to have muscle relaxation, the concentration of calcium needs to slow down. 
During the relaxation time when actin and myosin are not bound one to another, 
the filaments of the sarcomere slip back to the original position with the help of 
elastic connective tissue in the muscle. The stimulus for contraction comes from 
the central nervous system to the skeletal muscle via the motoneurons. The 
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acetylcholine coming from the motoneurons induce an action potential in the 
muscle fiber, inducing contraction. The combination of these electric and mechanic 
events is called excitation-contraction coupling. The acetylcholine from the 
synapsis at the neuromuscular junction binds to the receptor of the motor plaque. 
The colynergic receptors are cationic channels that allow the movement of Na+ and 
K+ across the sarcolemma. When the channels are open, the entrance of Na+ 
exceeds the exit of K+ because the electrochemical gradient is higher for Na+. In 
this way the membrane of the muscle fiber depolarizes, originating the potential 
plaque (PP). The PP gives origin to an action potential in the muscle that is 
conducted on the surface of the cell and in the tubuli T through the opening of the 
voltage-dependent Na+-channels. The potential of action that moves along the 
membrane and the tubuli T is responsible for the release of Ca2+ from the SR. The 
membrane of the tubuli T contains voltage-sensible receptors (VSR) mechanically 
linked to Ca2+ channel in the membrane adjacent to the SR. When a depolarisation 
wave reaches the VSRs, their conformation change: this variation open the Ca2+-
channels in the SR and the Ca2+ diffuse in the cytosol. As a consequence the 
cytoplasmatic concentration of calcium augments to 100 folds and in these 
conditions Ca2+ can bind to troponin and the tropomyosin frees the binding site of 
the F-actin for myosin. The muscle relaxation begins when the SR absorbs Ca2+ 
via a Ca2+-ATPase. There is a little period of latency between the muscular-action 
potential and the development of the muscular tension. This interval represents the 
time necessary for the excitation-contraction coupling. A single potential of action 
provokes a single shock in a muscle. The shocks differ among different muscle 
fibers because of the velocity required for the generation of the tension, maximum 
tension reached and duration of the shock. The contraction of muscle fibers 
requires a large amount of energy in the form of adenosine triphosphate (ATP). 
ATP is made available through various mechanisms. A limited amount of ATP is 
stored in the muscle cell (granules of glycogen). ATP is also produced by a 
phosphate transfer from creatine phosphate to ADP and muscle does store larger 
amounts of creatine phosphate. The stored ATP and the ATP created from creatine 
phosphate are available for immediate use and provide approximately enough ATP 
for about six seconds of exercise. Additional ATP can be produced through 
anaerobic and aerobic metabolism. Aerobic respiration provides a larger production 
of ATP but depends on sufficient oxygen delivery. Myoglobin, a protein in muscle 
cells that binds oxygen, contributes to some of the oxygen for aerobic respiration. 
Aerobic ATP production also requires mitochondria. Muscles packed with 
mitochondria give meat a darker colour ("dark meat") than muscles with fewer 
mitochondria ("white meat"). Anaerobic fermentation provides less energy but can 
produce ATP in the absence of oxygen. A serious drawback of anaerobic 
fermentation is the production of lactic acid, a product that can alter cell pH. Both 
processes can use glucose released from glycogen, which is stored in muscles as 
a reserve fuel. 
1.4 Classification of skeletal muscle fibers 
Skeletal muscle fibers can be classified in three groups depending on resistance to 
fatigue upon several stimulations and on the contraction-velocity: rapidly-
contracting glycolytic-fibers; rapidly-contracting oxidative-fibers; slowly-contracting 
oxidative-fibers. A decrease in the ability of muscle to contract is muscle fatigue. 
The fatigue is highly variable and is influenced by the intensity and duration of the 
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contractile activity, from the metabolism used, from the composition of the muscle 
and the degree of training. Otherwise the contraction velocity of a muscle is 
determined by the myosin isoform that constitutes the thick filaments. The various 
isoforms of myosin, in fact, differ in the ATPase activity and rapidly-contracting 
fibers are characterized by a higher velocity of ATP-hydrolysis. Also the duration of 
muscle contraction depends on the type of fibers constituting the muscle. More in 
detail, the time of shock persistence depends on the velocity of Ca2+-removal from 
the cytosol by the SR: when the Ca2+-concentration slows down, calcium 
dissociates from troponin so that tropomyosin partially blocks the binding sites for 
myosins. When the movement of the head-myosin is inhibited, muscle fibers relax. 
The efficiency of a muscle fiber to extract oxygen contributes in determining its 
metabolism. Slow fibers are also termed “red fibers” due to a big quantity of 
myoglobin, a red pigment that binds oxygen. They are also characterized by a 
smaller diameter, enabling a shorter route for the oxygen to reach mitochondria. 
Slow fibers major depends on oxidative phosphorylation. For these reasons, they 
are characterized by more mitochondria and more blood vessels. Fast fibers are 
also called “white fibers” because they are characterized by a minor content of 
myoglobin and vessels, and have a greater diameter. All these characteristics are 
responsible for the anaerobic metabolism of these fibers. They are subgrouped into 
other categories based upon their diameter and resistance to fatigue. In 
conclusion, there are two principal ways to classify muscle fibers: the type of 
myosin (fast or slow) present, and the degree of oxidative phosphorylation that the 
fiber undergoes. Skeletal muscle can thus be broken down into two broad 
categories: Type I and Type II. Type I fibers appear red due to the presence of the 
oxygen binding protein myoglobin. These fibers are suited for endurance and are 
slow to fatigue because they use oxidative metabolism to generate ATP. Type II 
fibers are white due to the absence of myoglobin and a reliance on glycolytic 
enzymes. These fibers are efficient for short bursts of speed and power and use 
both oxidative metabolism and anaerobic metabolism depending on the particular 
sub-type. These fibers are quicker to fatigue. A summary of fibre types and their 
features is reported in Table 2. 
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Short-term
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for
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Size of motor 
neuron
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Contraction
time
Type II b 
fibers
Type II x 
fibersType II a fibersType I fibers
 
Table 2: Muscle fibers type 
1.5 Muscle regeneration 
Adult skeletal muscle is a stable tissue with limited nuclear turnover [23], but it has 
the ability to rapidly regenerate in response to damage. The regeneration of 
skeletal muscle depends on the balance between pro- and anti-inflammatory 
factors that determine whether the damage will be repaired with muscle fiber 
replacement and functional contractility or with scar tissue formation [24, 25]. 
Skeletal muscle regeneration includes three distinct stages: degeneration, muscle 
repair and maturation, and follows a fairly consistent pattern irrespective of the 
underlying cause of injury (direct trauma, tissue ischemia, old age or genetic 
defects) [23]. If the muscle repair mechanisms are inadequate, the consequence 
might be reduced muscle function and muscle wasting [24]. The well-orchestrated 
course of satellite cell activation and differentiation is largely similar to the gene 
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expression during embryonic development of muscle while in myopathic patients 
the main difference is the presence of immune cells during muscle regeneration. 
The initial event in the degeneration of muscle, necrosis of muscle fibers, is 
triggered by disruption of the sarcolemma followed by increased serum levels of 
proteins such as creatine kinase and myoglobin [26, 27]. In the early phase of 
muscle damage, the injured muscle activates an inflammatory response driven by 
T helper (Th)1 cytokines, such as interferon (IFN) and tumour necrosis factor 
(TNF). Neutrophils are rapid responders within the first hours, followed by CD68-
expressing M1 phenotype macrophages during the first 24 h. These two cell types 
contribute to further muscle membrane lysis by production of free radicals but also 
clear the cellular debris by phagocytic removal [23]. Whether this elimination of 
debris is of importance for further regeneration is not fully understood. After the 
pro-inflammatory phase, quiescent Pax7- expressing muscle SCs are exposed to 
signals such as insulin-like growth factor 1 (IGF-1), fibroblast growth factor 2, and 
hepatocyte growth factor promoting activation, proliferation and migration to the 
site of injury [28]. During this stage, the cells become MyoD- and Myf5-expressing 
myoblasts. Throughout the shift from the proliferative stage to the differentiation 
phase, the M1 macrophages are replaced by CD163+ M2 macrophages, activated 
by Th2 cytokines such as interleukin-4 (IL-4), interleukin-10 (IL-10) and interleukin-
13 (IL-13) [29]. The M2 macrophages display a more anti-inflammatory phenotype 
and are found during the healing phase of acute inflammation, in wound-healing 
tissue and in chronic inflammation [23, 30]. Following the proliferation stage, 
expression of Myog and MRF4 is up-regulated, myoblasts exit the cell cycle and 
become terminally differentiated. These muscle progenitor cells fuse together or 
with the existing fibers to replace the damaged muscle cells [23]. 
1.6 Myogenic stem cells 
Although SCs represent the proper muscular resident stem cells (see section 1.1 
for details), other cell types able to differentiate into skeletal muscle can be 
recruited to support muscle regeneration under physiological or pathological 
conditions.  
1.6.1 Muscle-derived cells 
Qu-Petersen and colleagues isolated three populations of muscle-derived cells 
(MDSC) according to their adhesion characteristics and proliferation behaviours 
[31]. Two of them - the early preplate cells (EP) and  the late preplate cells (LP) - 
are populations of satellite cells based on their patterns of myogenic marker 
expression and their behavior in vitro. The majority of the EP cells expressed the 
myogenic markers desmin, m-cadherin and myogenin [32], suggesting that EP 
cells represent a late myogenic precursor. Similarly to satellite cells [33, 34], the EP 
cells exhibited a very fast but limited ability to proliferate and a strong capacity to 
differentiate into myotubes. Unfortunately, they showed a limited capacity to 
regenerate skeletal muscle after transplantation. The LP population represented 
1% of satellite cells: they demonstrated a very limited capacity to proliferate and 
differentiate and so that their function in skeletal muscle remains unclear. The last 
population, called MDSC, derived from primary LP cultures and represented highly 
proliferating cells: they maintained the same phenotype for a long period of time in 
vitro, indicating they were capable of self-renewal in vitro. Moreover, the detection 
of donor-derived cells in myofibers, peripheral nerves, and blood vessels within the 
 15 
 
MDSC-injected muscle demonstrated the multipotent nature of MDSC in vivo, 
when appropriately stimulated with growth factors [31]. According to several 
features such as their differentiation potential, their ability to express myogenic 
markers, and their similarity in phenotype to a subpopulation of cells that were 
identified within the basal lamina of myofibers [35], it was suggested that MDSC 
derived from skeletal myofibers [31].  
1.6.2 Myo-endothelial cells 
Few years ago, Nishikawa et al. demonstrated that endothelial cells could give rise 
to hematopoietic stem cells, suggesting as endothelial cells may have additional 
differentiation potential [36-38]. At the same time, other groups showed that 
MDSCs could express endothelial cell markers and differentiate into endothelial 
cells after muscular injection and promote angiogenesis [31, 39, 40]. According to 
these observations, Zheng and colleagues provided evidence for the existence of 
myogenic cells related to the endothelial cell lineage in human skeletal muscle [41]. 
They were able to isolate between muscle fibers a subpopulation of cells that co-
expressed Pax7 and endothelial cell markers;  they purified by flow cytometry rare 
muscle cells co-expressing the myogenic cell antigen CD56 and the endothelial cell 
markers CD34 and CD144; and, starting from CD56+ myogenic cells, they 
identified several cells that expressed both myogenic and endothelial cell markers. 
The main conclusion of this study was that human muscle–derived endothelial cells 
(CD56–CD34+CD144+) and myo-endothelial cells (CD56+CD34+CD144+) 
regenerated skeletal muscle more efficiently compared with myogenic cells 
(CD56+CD34–CD144–). Furthermore they demonstrated that myo-endothelial cells 
possessed good myogenic potential, due to fast proliferation rate and high 
resistance to oxidative stress.  
1.6.3 Mesoangioblasts 
Mesoangioblasts are multipotent progenitors of mesodermal tissues, physically 
associated with the embryonic dorsal aorta in avian and mammalian species. 
Cossu and Bianco [42] demonstrated the capacity of mesoangioblasts to 
differentiate in various mesodermal phenotypes so that these progenitors were 
considered as a novel class of stem cells. These cells expressed Flk-1, stem cell 
antigen 1, CD34 - known to be early endothelial markers [42] - and many of the 
leukocyte molecules implicated in transmigration [43]. Moreover, they differentiated 
into mature smooth muscle that expressed smooth muscle myosin upon treatment 
with TGF-β [44]. 
1.6.4 Perycites 
Among the various cells that constituted the bone marrow - CD34+ and CD34- 
haematopoietic and mesenchymal stem, progenitors cells - putative muscle-
specific progenitors [45], distinct from satellite cells [46], were identified. These 
cells were identified as pericytes: they wrapped around the vascular tube and 
interdigitated with the endothelial cells in the basement membrane of the vessels. 
Pericytes played a fundamental role in the maintenance of microcirculation 
functionality and they can be also mobilized from adult bone marrow under 
ischemic conditions and utilized for their contractile capabilities and their multiple 
cytoplasmic processes [47]. They seemed to be progenitor cells for mesenchymal 
cells such as osteoblasts and adipocytes; however Dellavalle and colleagues 
demonstrated that pericytes had good capacity of myogenic differentiation [46]. 
Moreover, it was proposed that the pericytes could be released from its position on 
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a vascular tube in the case of a focal injury and functioned as immunomodulatory 
and trophic mesenchymal stem cell [48]. According to these evidences, the activity 
of pericytes ensured that the field of damage remained limited and that tissue-
intrinsic progenitors replaced the expired cells. 
1.6.5 CD133+ cells 
In 2003, Stamm and colleagues demonstrated that autologous bone marrow-
derived CD133+ cells could induce angiogenesis and restore myocardial tissue 
viability after infarction [49]. In 2004, Torrente et al. published the stem cell 
characteristics of human circulating CD133+ cells and their ability to restore skeletal 
muscle and eventually regenerate the satellite cell pool after intra-muscular and 
intra-arterial delivery [50]. Few years after, the same group isolated CD133+ cells 
from muscle also co-expressing CD34, CD45, Thy-1 and KDR. The ability of these 
cells to express myogenic markers and/or to undergo myogenic differentiation was 
consistently evaluated in vitro [51]. RT-PCR analysis revealed the expression of 
Pax-7, Myf-5, MyoD, m-cadherin, MRF-4, and myogenin after 24 days of culture 
into proliferative medium. In addition, CD133+ cells differentiated into 
multinucleated myotubes expressing MyHCs. 
1.6.6 PW1+/Pax7- interstitial cells 
Although the contribution to myogenesis of non-satellite cell progenitors has been 
extensively reported [52, 53], as a consequence of the methods used to isolate 
these myogenic progenitors, critical information is missing regarding the precise 
anatomical localization of these cells, as well as their physiological contribution to 
muscle growth and repair [54-56]. Trying to overcome these limitations, Mitchell et 
al. described a new population of muscle-resident stem cells located in the 
interstitium and expressing the cell stress mediator PW1 [57]. These so-called 
PW1+/Pax7- interstitial cells (PICs) were more abundant at birth and declined until 
about 2–3 weeks after birth, maintaining a 1:1 ratio with satellite cells. It was 
demonstrated that PICs were a significant myogenic progenitor population as they 
participated in myogenesis in vivo at levels comparable to those obtained with 
freshly isolated satellite cells. PICs required Pax7 for myogenic specification and 
expressed Pax3 during myogenic commitment. Notably, PICs re-populated their 
niche at high levels (as a stem cell) however only PICs gave rise to more PICs in 
addition to satellite cells and myofibers [57]. Furthermore, it had to be determined 
whether PICs are a source of satellite cells during normal postnatal development. 
1.6.7 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) reside within the stromal compartment of bone 
marrow. They play a fundamental role in providing the support system for 
haematopoietic stem cells in the marrow and constitute a very small fraction, 
0.001–0.01% of the total population of nucleated cells in marrow [58]. Importantly 
they have the capacity to differentiate into several tissues, included skeletal 
muscle. Moreover, MSC-like cells were recently isolated from human healthy 
muscle tissue biopsies [41] an/or surgical waste tissues [59]. As these cells could 
be obtained with non- or minimally invasive-biopsy procedures, skeletal muscle 
could be an important clinical source of MSCs for use in therapeutic applications. 
However even if MSCs do not con tribute massively to muscle regeneration, they 
could have a therapeutic effect by either producing extracellular matrix molecules 
[60], or reducing inflammation [61]. MSCs played multifactorial roles in controlling 
inflammation as selectively home towards damaged tissue via expression of 
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receptors for SDF-1, lysophosphatidic acid [62], and CCL2 [63]. Di Bari and 
collaborators described the myogenic potential of adult human synovial membrane-
derived mesenchymal stem cells (hSM-MSCs) [64]. They also demonstrated their 
myogenic differentiation in a nude mouse model of skeletal muscle regeneration: 
when implanted into regenerating nude mouse muscle, hSM-MSCs contributed to 
myofibers and to long term persisting functional satellite cells [64]. MSCs were also 
isolated from adipose tissue: these cells, called adipose-derived stem cells (ASCs), 
transplanted in a rat ischemic model, improved the vascular compartments [65, 66], 
ameliorating myocardial regeneration [67, 68]. 
2. Calcium ion in skeletal muscle 
The calcium ion is an ubiquitous intracellular signal responsible for controlling 
numerous cellular processes including growth and differentiation, metabolism, and 
regulation of gene expression. Free Ca2+ concentration in the cytoplasm is 
modulated by two different mechanisms, the entry of external calcium (influx of 
calcium) and the release of calcium from internal stores. Since prolonged high 
intracellular calcium levels are highly toxic and lead to cell death, once calcium has 
carried out its signaling functions, the initial concentration is rapidly restored in the 
cytoplasm, principally by the calcium pump [69-71]. 
2.1 Calcium signaling in muscle development 
Changes in cytosolic Ca2+ in muscle can be converted into biochemical changes 
through activation of signal transduction cascades that are require Ca2+/calmodulin 
for activation. Examples of these cascades include signaling through calmodulin 
kinases (CamK) or the Ca2+/calmodulin-activated serine-threonine phosphatase, 
calcineurin, where changes in Ca2+ concentration can influence the 
phosphorylation state of key target proteins [72, 73]. It is through these signaling 
cascades that Ca2+ can influence skeletal muscle development and differentiation. 
During muscle development and muscle regeneration, myoblasts proliferate and 
then undergo a highly ordered process of myogenic commitment in which they 
leave the cell cycle and express muscle specific proteins [74]. Myoblasts then 
migrate and align with each other, and ultimately undergo fusion with one another 
to form primary myotubes. Myoblasts then fuse with the primary myotubes 
generated in this manner to form secondary myotubes. A multitude of elements are 
critical for the process of myoblast fusion including membrane-associated proteins, 
signaling complexes, and extracellular/secreted molecules [75]. Calcium plays a 
critical role in multiple steps involved in myotube formation. Calcium activates 
intracellular cysteine proteases, calpains, which are required for cytoskeletal re-
organization during migration and cell fusion [76]. Increased intracellular calcium 
also activates calcineurin, a serine-threonine phosphatase, involved in the 
downstream activation of MEF-2 and the NFAT family of transcription factors which 
have been shown to regulate myotube development [77-80]. Ca2+-calmodulin can 
also influence muscle specific gene expression through the activation of the 
CamKII pathway [81]. Here, CamKII can influence MEF2 signaling by altering the 
actions of class II histone deacetylases (HDAC) [82]. In addition CamKII can 
stimulate the expression of peroxisome proliferator-activated receptor gamma 
coactivator 1 (PGC-1), a master regulator of mitochondrial biogenesis [73]. Finally, 
calmodulin can also influence the actions of a transcriptional coactivator called 
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calmodulin binding transcriptional activator (CAMTA). CAMTAs are known to 
activate cardiac transcription through a mechanism that involves class II HDACs 
[83]. Interestingly, dCAMTAs have been implicated in phototransduction of the 
drosophila eye [84]. Here, mutants of CAMTA signaling reveal a defect in the 
deactivation of rhodopsin. Given the critical importance of TRP channels in 
phototransduction, it is likely that Ca2+/calmodulin from TRP channels are required 
to activate CAMTA dependent transcription. Interestingly, several recent studies 
have demonstrated the importance of TRPC channels to striated muscle 
development, degeneration and performance [85-87]. It will be important to 
determine if CAMTAs have a role in the TRPC response of Ca2+ dependent gene 
expression in skeletal muscle. Furthermore, a deeper knowledge of the specific 
pathways by which Ca2+ signaling influences gene expression in muscle will be 
important in our understanding of how these events occur during muscle 
development and are altered during the adaptation response to exercise or in the 
pathogenesis of myopathies. Transient receptor potential (TRP) channels have 
previously been shown to function in axonal pathfinding during neuronal 
development [88]. TRP channel activation by local growth factor concentrations 
allows for extension or retraction of axonal processes [89]. Recent studies have 
also implicated transient receptor potential channels in myotube development. 
Rosenberg and colleagues previously showed that overexpression of TRPC3 in 
C2C12 myotubes resulted in increased NFAT transactivation: a process involving 
activation of calcineurin by Ca2+ influx, dephosphorylation of NFAT by calcineurin, 
translocation of NFAT to the nucleus, and DNA binding by NFAT resulting in 
altered gene expression [85]. Similarly the scaffolding protein Homer, which has 
been shown to bind to multiple members of the TRP channel family, is expressed 
as part of the myogenic differentiation program and promotes myotube 
differentiation through modulation of calcium-dependent gene expression [90]. 
Homer enhanced calcium signaling via the calcineurin/NFAT pathway resulting in 
greater activation of a muscle-specific transcriptional program [91]. Evidence also 
suggests that TRPC1 may be a route for calcium influx required for calpain 
activation during myoblast migration and fusion. Migration of C2C12 myoblasts was 
inhibited by GsMTx-4 peptide, an inhibitor of mechanosensitive channels, and Z-
Leu-Leu, an inhibitor of calpains. Knockdown of TRPC1 in C2C12 myoblasts 
resulted in decreased calpain activity, reduced cell migration, and a reduction in 
myotube fusion [92]. Growth factor stimulation resulted in increased calcium influx, 
calpain activity, and accelerated migration which was blocked by TRPC1 
knockdown [92]. TRPC1 has also been shown to play a role in 
mechanotransduction during myotube development. TRPC1 knockdown inhibited 
stretch-activated calcium influx in C2C12 myoblasts in response to atomic force 
microscopic pulling and blocked stretch-activated current assessed by the whole-
cell patch clamp technique [93]. TRPC1 activity was negatively regulated by 
cholesterol depletion, suggesting that TRPC1 was functionally assembled in lipid 
rafts, but enhanced by sphingosine-1-phosphate suggesting a role for stress fibers 
and cytoskeleton in TRPC1 recruitment [93]. 
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2.2 Calcium and skeletal muscle function: excitation-contraction 
coupling 
Skeletal muscle fibers are unique cells. They are large, elongated and specialized 
for the rapid delivery of large amounts of Ca2+ to the contractile apparatus for 
periods of work. Their membrane architecture has evolved to create a signaling 
microdomain between the invaginations of the surface membrane, the transverse 
(t–) tubules and the sarcoplasmic reticulum (SR). The t–tubules and their junction 
with the terminal cisternae of the SR are specifically aligned along the A–I bands in 
the sarcomere of mammalian skeletal muscle. This region is referred to as the 
junctional membranes, and there is only a 10–15-nm gap between them, which is 
spanned by the dihydropyridine receptor (DHPR)/voltage sensor on the t–tubule 
and the ryanodine receptor (RyR)/Ca2+ release channel on the SR membranes [94, 
95]. Note that the SR is a specialization of the ER in muscle cells. Via the process 
known as excitation–contraction coupling (EC coupling), these proteins convert the 
electrical signal propagating (action potential) from the surface membrane down 
through the t–tubules to a mechanical signal that activates the opening of the SR 
Ca2+ release channels. Ca2+ is released rapidly from the SR to the cytoplasm, and 
the increase in [Ca2+]cyto causes Ca2+ to bind to troponin C (TnC) on the contractile 
proteins to initiate contraction. The muscle fiber relaxes as Ca2+ is pumped back 
into the SR via Ca2+ pumps located on the SR, returning [Ca2+]cyto to resting levels 
[95] (Fig. 8). This re-sequestration is performed by the actions of the 
sarco/endoplasmic Ca2+-ATPase pump (SERCA1) and mitochondrial calcium 
buffering and is critical for relaxation of skeletal muscle fibers [96]. SERCA1 can 
refill calcium stores faster than the other SERCA isoforms: SERCA2a and SERCA3 
[97]. Other plasma membrane calcium pumps such as the plasma membrane Ca2+-
ATPase (PMCA) and Na+/Ca2+ exchanger (NCX) are known to exist in the 
sarcolemma and work to rapidly lower cytosolic Ca2+ levels in order to relax the 
myofiber [98-100]. ATP is hydrolyzed by the Ca2+ pumps and contractile proteins 
during these processes, increasing the concentrations of ADP, Mg2+ and inorganic 
phosphate, which has implications for the regulation of Ca2+ during EC coupling 
[101]. In the EC coupling cycle, [Ca2+]SR is buffered by a dynamic Ca2+ buffer, 
calsequestrin (CSQ) [102, 103]. Indeed as [Ca2+]SR drops the aggregation state of 
CSQ is reduced from polymers to dimers and monomers. This reduces the Ca2+–
buffering ability of CSQ as the affinity of Ca2+ for CSQ changes with the changing 
aggregation state of CSQ [104-107].  
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Figure 8: Schematic summary of excitation-contraction phases 
(Copyright 2001 Benjamin Cummings, an imprint of Addison Wesley Longman, Inc.) 
 
2.3 Store-operated calcium entry in skeletal muscle  
The concept of store-operated calcium entry (SOCE) was first introduced in 1986 
when series of experiments suggested that depletion of internal Ca2+ stores 
controlled the extent of Ca2+ influx in nonexcitable cells [108]. This mechanism of 
Ca2+ entry served as a link between extracellular Ca2+ and intracellular Ca2+ stores. 
When the stores were full, no Ca2+ influx was detected, but when the stores were 
emptied, Ca2+ entry developed. This model, initially called capacitative calcium 
entry (CCE), was later supported by electrophysiological studies which established 
that depletion of Ca2+ stores activated a Ca2+ current in mast cells called the Ca2+ 
release-activated Ca2+ current, or ICRAC [109]. While the electrophysiologic 
properties of SOCE currents have been well documented, the molecular 
components of the underlying channels and the mechanism by which a cell senses 
store depletion and activates SOCE had remained elusive for many years. In 2005, 
independent groups used RNA interference (RNAi)-based screens to identify 
STIM1 as a key component of SOCE [110, 111]. STIM1 is a single-pass, 
transmembrane phosphoprotein that was initially cloned from stromal cells involved 
in pre-B cell differentiation and implicated as a tumor suppressor for rhabdoid 
tumors and rhabdomyosarcoma cell lines [112]. Two homologues of Drosophila 
STIM (dSTIM) have been identified in vertebrates, STIM1 and STIM2. The 3D 
structure of STIM1 has been predicted based on the amino acid sequence and 
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includes an EF-hand domain, a sterile-α-motif (SAM) domain, a transmembrane-
spanning region, coiled-coil regions, and proline-rich N terminus [113]. The EF-
hand domain of STIM1 has a high affinity for calcium (200–600µM range) and is 
located in the lumen of the ER where it senses changes in calcium store content 
[114]. The SAM domain of STIM1 is a protein–protein interaction domain that is 
also located in the lumen of the ER, a location not previously described for other 
SAM domain-containing proteins [115]. The cytosolic coiled coil domains are 
located at the C-terminus and are important for oligomerization and punctae 
formation that is required for activation of SOC channels [116]. Simultaneously with 
the identification of STIM1, Orai1 was identified in siRNA-based screens for 
mediators of SOCE and was found to be mutated in immunodeficient patients that 
lacked SOCE [117-119]. The Orai family of calcium entry channels includes three 
members and bares little resemblance to other ion channel families. Orai proteins 
are predicted to have four transmembrane spanning regions and share structural 
similarities with the gamma subunit of the L-type calcium channel (CaV gamma), 
transmembrane AMP receptor proteins and claudins [120]. Two studies analyzing 
mutations in the membrane spanning region of Orai1 demonstrated an altered ion 
selectivity of Icrac, indicating that Orai proteins represent the pore for ICRAC [121-
123] (Fig. 9).  
 
Figure 9: Orai1 and STIM1. Schematic representation of Orai1 and STIM1 
domains and subcellular localization. (Adapted from [124]). 
 
When the [Ca2+] of the ER ([Ca2+]ER) is at normal resting levels, STIM1 and Orai1 
are sparsely distributed across the ER and plasma membrane, respectively. A 
depletion of [Ca2+]ER causes STIM1 monomers to begin to aggregate until they 
form tetramers just below the plasma membrane. This may require translocation of 
part of the ER towards the plasma membrane so the ER comes within 10–25 nm of 
the plasma membrane [125]. At this location, Orai1 monomers aggregate to form a 
tetramer in response to the aggregation of STIM1 at this location [126]. STIM1–
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Orai1 complexes form functional units that regulate and conduct the store-
dependent Ca2+ influx, and a physical contact between the STIM1 tetramer and the 
Orai1 tetramer activates Ca2+ influx [127]. These events take seconds to tens of 
seconds to occur [124] (Fig. 10). These SOCE functional units can only form at a 
low density around the periphery of the cell, probably due to a relatively low 
abundance of these proteins in non–muscle cells and also due to infrequent 
plasma membrane–ER contacts. 
 
Figure 10: Steps of SOCE. In resting cells (left panel), STIM1 and Orai1 are 
dispersed throughout the ER and plasma membrane, respectively. Store depletion 
causes STIM1 to accumulate at locations where the ER is juxtaposed to the 
plasma membrane ('junctional ER'). At the same time, Orai1 accumulates in 
regions of the plasma membrane directly opposite the STIM1 clusters. The co-
localization of STIM1 and Orai1 restricts channel activation and Ca2+ entry to these 
sites (right panel). (Adapted from [128]). 
 
Compared with skeletal muscle fibers, the non-excitable cells in which SOCE has 
been well described, represent cells that do not require a rapid and precise delivery 
of Ca2+. This is reflected in a less-developed Ca2+ regulatory membrane system as 
compared with skeletal muscle fibers. Skeletal muscle fibers have become 
specialized in the rapid delivery and storage of Ca2+ for the purpose of supporting 
rapid and frequent contraction [129]. It also appears that SOCE has become 
specialized in skeletal muscle fibers. Calcium entry into a myofiber from the 
extracellular space has been largely overlooked as a mechanism of store refilling. 
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However, a recent challenge to the long held notion that muscle contraction can 
continue in the absence of external calcium was offered by studies demonstrating 
that repeated stimulation of isolated muscle fibers without external calcium results 
in the depletion of internal stores and loss of EC coupling [130]. As a consequence 
of store depletion, muscles fatigue and lose the ability to generate force. These 
effects are reversed by adding calcium to the perfusion bath [131, 132]. This 
mechanism, demonstrated in myogenic cell lines, primary embryonic myotubes, 
and isolated single myofibers, suggests an unrecognized but important role for 
SOCE in  skeletal muscle function. Although the main actors of this trans-
sarcolemmal Ca2+ flux have been identified [110, 111, 117, 119, 133]; there are still 
several important unresolved issues regarding SOCE in skeletal muscle, including 
the identification of mechanisms and molecules involved in the fine regulation of 
this pathway. The MS4A family includes proteins that share a predicted tetra-
spanning membrane topology with N- and C-terminal cytoplasmic domains. CD20, 
the best studied member of this family, is conventionally expressed on the surface 
of B cells where it is involved in lymphocyte activation, proliferation, and 
differentiation [134]. The primary structure of CD20 indicates a multi-
transmembrane domain configuration resembling that of ion channels or 
transporters [135]. Cell lines transfected with CD20 show an increased calcium 
conductance across the plasma membrane, strongly suggesting that CD20 
functions as an important channel for regulating calcium homeostasis [136, 137]. 
Furthermore, reduced CD20 expression in B cell lines results in significantly 
decreased calcium entry across the plasma membrane [137, 138]. Beyond these 
findings, knowledge about the biology of CD20 is relatively scarce, and its precise 
functionality is still not understood. Remarkalby, some insight has been provided by 
studies showing that CD20 can associate with lipid raft domains of the plasma 
membrane, where it is probably involved in SOCE [139, 140]. Other critical details 
such as the kinetics of SOCE activation, the extent of store depletion required to 
activate SOCE, and even the functional role of SOCE in skeletal muscle remain to 
be defined [141]. However, it is possible to asses potential roles of SOCE in 
skeletal muscle by modeling. Ca2+ entering the fiber via SOCE could be to 
supplement [Ca2+]cyto for contractile activation, refilling of the SR, simple balancing 
of Ca2+ fluxes across the surface membrane or perhaps even to regulate protein 
function within the junctional cleft. The role of SOCE in activating the contractile 
apparatus directly can be addressed by comparing the known Ca2+ flux rates to the 
cytoplasm from the SR and t–system. Even under conditions of maximum 
physiological DFCa, the flux rate of SOCE is some four orders of magnitude smaller 
compared to the SR Ca2+ release flux [142, 143]. As such, the store–dependent 
influx probably only introduces Ca2+ into the junctional membrane regions and thus 
there would not be a significant contribution from SOCE to the cell–wide Ca2+ 
transient during EC coupling (the role of SR Ca2+ release). Clearly, this rules out a 
role of SOCE directly providing any significant Ca2+ for contraction. The potential 
role of SOCE in refilling the SR to provide Ca2+ for continuing release from SR in 
fast–twitch muscle can be scrutinized also from known Ca2+ influx rates to the 
cytoplasm. The contribution is only significant under the assumption that Ca2+ 
release from SR is at its lowest (∼25-µM per action potential) and stimulation 
frequency is ∼5 Hz or lower. This indicates the contribution of SOCE to SR refilling 
in active fast–twitch muscle can only be minimal, if any. It should be noted that the 
amount of Ca2+ released during trains of action potentials in slow–twitch muscle is 
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much less than that in fast–twitch muscle [142]. Therefore, SOCE may contribute 
to the refilling of the SR of slow-twitch muscle under similar circumstances. A 
simpler role of SOCE, where SOCE may be providing a balancing influx of Ca2+ to 
maintain a consistent [Ca2+] in the cell, remains possible. As [Ca2+]cyto is high during 
prolonged EC coupling, extrusion mechanisms must eject some Ca2+ from the 
fiber. Replacing Ca2+ that is lost during such times may be the role of SOCE in 
muscle. All these possible roles need to be examined to allow for an in–depth 
understanding of SOCE in regulating muscle fatigue resistance, Ca2+-related 
signaling, muscle development, and disease. 
3. Myopathies 
Diseases affecting skeletal muscle are defined as myopathies and are caused by a 
structural or functional alteration of the muscle. Myopathies can be hereditary or 
acquired. In particular, the muscular dystrophies (MDs) are inherited myogenic 
disorders characterized by progressive muscle wasting and weakness of variable 
distribution and severity [144, 145]. They share common histological features of 
‘‘dystrophic’’ muscle biopsy changes that include variation in muscle fibre size, 
muscle fibre degeneration and regeneration, and replacement of muscle by 
connective tissue and fat [145-148]. The clinical and genetic heterogeneity of these 
conditions is well recognized, since differences arise comparing onset, disease 
progression and multisystem involvement [145]. The genes and their protein 
products that cause most of these disorders have now been identified. This 
information is essential to establish an accurate diagnosis and for reliable genetic 
counselling and prenatal diagnosis. Nevertheless there is, as yet, no way of greatly 
affecting the long-term course of any of these diseases. The major advances over 
the last two decades have in fact improved diagnostic precision and focused 
symptomatic management and are increasingly leading to development of cutting-
edge therapies. 
Based on distribution of predominant muscle weakness, six major forms can be 
delineated (Fig. 11): Duchenne and Becker type, Emery-Dreifuss, limb-girdle, 
Facioscapulohumeral, distal, oculopharyngeal, with the addition of congenital 
dystrophy, in which muscle weakness is more generalized. 
 
   
Figure 11: Distribution of predominant muscle weakness and wasting. (A) 
Duchenne Muscular Dystrophy, (B) Emery-Dreifuss, (C) Limb-girdle, (D) 
Facioscapulohumeral, (E) Distal, and (F) Oculopharyngeal muscular dystrophy. 
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3.1 Duchenne muscular dystrophy 
Many of the dystrophies, but not all, are diseases of the dystrophin-glycoprotein 
complex and are today classified as dystrophinopathies. Duchenne Muscular 
Dystrophy (DMD) is the best known since it is one of the most frequent genetic 
human diseases (~1:3500 male births; [149]). The primary defect in DMD is the 
lack of dystrophin, a 427 kDa subsarcolemmal cytoskeletal protein, due to 
mutations in the dystrophin gene which is extraordinarily large (>2300 kB) and 
localized on the X chromosome at Xp21. Full-length dystrophin is a large rod-
shaped protein that comprises four domains. The amino-terminal domain has 
homology with α-actinin and contains between 232 and 240 amino-acid residues 
depending on the isoform. The central - rod - domain is a succession of 25 triple-
helical repeats similar to spectrin and contains about 3000 residues. There is a 
cysteinerich domain of 280 residues. The last - carboxy-terminal - domain 
comprises 420 residues [150-156]. The protein is associated with the plasma 
membrane of cardiac and skeletal muscle (sarcolemma) and its main role at the 
sarcolemma is to interact with integral membrane proteins (sarcoglycan, 
dystroglycans, syntrophin, and dystrobrevin complexes) that are assembled in the 
dystrophin–glycoprotein complex. This complex forms a bridge across the 
sarcolemma and flexibly connects the basal lamina of the extracellular matrix to the 
inner cytoskeleton [157, 158]. Furthermore, dystrophin interacts with the 
sarcomeric network by binding to F-actin [152, 157] (Fig. 12). One of the main roles 
of the dystrophin–glycoprotein complex is to stabilise the sarcolemma and to 
protect muscle fibres from long-term contraction-induced damage and necrosis 
[153, 157, 159-161]. In addition to its mechanical function, dystrophin–glycoprotein 
complex has recently been suggested to have a role in cellular communication by 
acting as a transmembrane signalling complex [157, 162]. This hypothesis is 
supported by the fact that the mechanisms of cell death due to mutations of the 
dystrophin–glycoprotein complex genes might be related to disruption of cell 
survival pathways and cellular defence mechanisms that are regulated by 
signalling cascades [157]. Dystrophin is also the target of a proline-directed, 
serine–threonine, and calmodulindependent kinase and is phosphorylated both in 
vivo and in vitro [157]. Although it has been shown that dystrophin phosphorylation 
affects its affinity for F-actin and syntrophin [163, 164], the phosporylation status 
might have a role in signal transduction. 
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Figure 12: Dystrophin-glycoprotein complex 
 
The dystrophin gene also has at least four internal promoters that give rise to 
shorter dystrophin proteins lacking the actin-binding terminus but retaining the 
cysteine rich and carboxy-terminus domains that contain the binding sites for 
dystroglycan, dystrobrevin, and syntrophin. Each of these internal promoters uses 
a unique first exon that splices into exons 30, 45, 56, and 63 to generate protein 
products of 260 kDa (Dp260), 140 kDa (Dp140), 116 kDa (Dp116), and 71 kDa 
(Dp71) (Fig. 13). Dp260 is expressed in high concentrations in the retina, where it 
coexists with the full-length brain and muscle isoforms [165, 166]. Dp140 is 
expressed in brain, retina, and kidney tissues [167]. Dp116 is only expressed in 
adult peripheral nerves [168]. Dp71 is detected in most non-muscle tissues 
including brain, retina, kidney, liver, and lung and it is present in cardiac but not 
skeletal muscle [169]. This isoform is commonly alternatively spliced such that the 
13 carboxy-terminal dystrophin amino acids are replaced with a stretch of 31 new 
ones [170]. 
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Figure 13: Organization of the dystrophin gene. (A) Dys gene is located in 
Xp21. Arrows indicate the various promoters: in particular are brain (B), muscle 
(M), and Purkinje (P) promoters; R, B3, S, and G represent the Dp260 (retinal), 
Dp140 (brain), Dp116 (Schwann cell), and Dp71 (general) promoters. (B) The 
domain composition of the various dystrophin proteins is indicated. (Adapted from 
[171]). 
 
More than 1500 deletion breakpoints have been detected in the human dystrophin 
gene only in European populations [172]. Today it seems clear that all DMD 
patients lack dystrophin independent of the underlying mutation, and it is believed 
that the absence of a functional protein accounts for the dystrophic phenotype. In 
DMD, the first clinical symptoms are usually observed before the age of three in 
affected boys who show a delay in reaching developmental milestones such as 
running and climbing. Before the age of 6, their gait becomes unsafe and waddling, 
and in the same period of time hypertrophy and pseudohypertrophy of calf, gluteal, 
quadriceps, and other muscles develops. Between 6 and 11 years of age muscle 
strength declines steadily, leaving boys wheelchair bound from about age 11. 
Death occurs before age 30 by respiratory failure (as a consequence of weakness 
of respiratory muscles) often in combination with respiratory infection or by cardiac 
failure [173]. The histological analysis of DMD muscle characteristically reveals 
eosinophilic hypercontracted muscle fibers, necrotic fibers, ongoing muscle 
regeneration, and the proliferation of fibroblasts within muscle tissue. The 
replacement of muscle tissue by connective tissue (fibrosis) is the major cause of 
muscle weakness. Several animal models of muscular dystrophy exist, including 
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the mdx mouse [149, 174]. Degeneration and regeneration of muscle fibers does 
also occur in mdx muscle, but fibrosis is seen to a much smaller extent and has a 
late onset [149]. 
3.2 Calcium as a pathogenic factor in DMD  
Although the primary defect in DMD has been known for more than 20 years [175], 
neither the function of dystrophin nor the pathogenic mechanism of muscle 
dystrophy is sufficiently clarified. Two different, not necessarily exclusive, 
hypotheses have been put forward to explain the pathological changes caused by 
dystrophin deficiency, i.e., the “calcium hypothesis” and the “leaky membrane 
hypothesis” [149, 176-178]. The calcium hypothesis is based on early reports of 
Ca2+ accumulation in DMD muscle fibers. An alizarin red stain, a histochemical 
stain for Ca2+ deposits, showed increased numbers of positive fibers in DMD 
muscle compared with controls. Necrotic as well as non-necrotic fibers were 
alizarin red positive [179]. The total Ca2+ content of DMD muscle biopsies was 
found to be elevated compared with controls by a factor of 2.4 [180]. A similar Ca2+ 
increase was found in adult mdx muscles at all tested stages [181]. The 
mechanism of Ca2+ entry and its connection to dystrophin deficiency are still 
controversially discussed. An increased activity of plasma membrane Ca2+ 
channels in myotubes of DMD and mdx origin has been reported [182, 183]. 
Elevated resting levels of intracellular free Ca2+, detected with fluorescent 
indicators, were observed in DMD myotubes [184] and mdx muscle fibers [185]. 
These data suggested a direct or indirect involvement of dystrophin in the muscular 
Ca2+ homeostasis and a close correlation between the lack of dystrophin and 
increased Ca2+ influx. In later studies, these findings could not be confirmed. 
Several groups showed unchanged free Ca2+ resting levels and Ca2+ transients in 
cultured myotubes of DMD and mdx origin [186, 187] and in mdx muscle fibers 
[186, 188, 189]. Interestingly, hyposmotic stress, a means to mimic mechanical 
stress, induced Ca2+ transients in myotubes [186], and they were more pronounced 
in mdx myotubes [190]. Contracting but not resting DMD myotubes, cocultured with 
spinal cord tissue, were more sensitive to hyposmotic shock than the controls 
[191]. Recently, the question of increased membrane Ca2+ permeability of 
dystrophin-deficient muscle was reinvestigated with the “manganese quench 
technique.” Bath application of Mn2+, an ion known to quench fura 2 fluorescence, 
caused a faster progressive quench of intracellular fura 2 in mdx myotubes [183] 
and in adult mdx fibers [192] compared with controls. The effect could be inhibited 
by Gd31, other unspecific ion channel blockers, and amiloride. These observations 
indicate an increased Ca2+ flux through ion channels into mdx fibers. This influx is 
probably fairly well compensated by effective cellular Ca2+ transport systems, 
because resting Ca2+ levels were nearly unchanged. According to present 
knowledge, intact dystrophin-deficient muscle fibers can have normal free levels 
both at rest and after contractile activity. However, aggravated mechanical activity 
or mechanical stress can cause abnormally high and persistently increased Ca2+ 
levels in DMD and mdx muscle.  
According to the leaky membrane hypothesis, the sarcolemma of dystrophin-
deficient muscle fibers is more susceptible to lesions. This hypothesis was 
developed on the observation that increased concentrations of muscle-specific 
cytoplasmic proteins are present in the serum of DMD patients [173, 193, 194] and 
mdx mice [181, 195] even before the onset of muscle fiber degeneration. Creatine 
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kinase (CK) activity can be 100-fold higher in serum of DMD patients compared 
with controls [194]. In addition to CK, many other muscle-specific cytoplasmic 
proteins as pyruvate kinase, myoglobin [193], and PV [196] are found in the serum 
when skeletal muscle is dystrophin deficient. The release of cytoplasmic enzymes 
from dystrophin-deficient muscle has been reproduced with isolated muscle fibers 
[197] and cultured mdx and DMD muscle [198]. Not only efflux, but also influx of 
molecules into dystrophin-deficient muscle fibers has been shown in vitro and in 
vivo. Preparations of isolated mdx diaphragm exposed to eccentric contractions 
showed much higher intake of procion orange than control muscle [199]. This result 
was later confirmed with extensor digitorum longus muscle from 40-day-old but not 
from 2-wk-old mdx mice [195]. Matsuda et al. [200] demonstrated that uptake of 
molecules into mdx muscle fibers does occur in vivo. Intravenous injection of 
Evan’s blue resulted in staining of mdx muscle fibers, indicating the uptake of the 
dye, which is in plasma bound to albumin, into dystrophin-deficient muscle fibers 
[153, 178, 200]. Evans blue does not cross into skeletal muscle fibers in normal 
mice [178]. Taken together, a bidirectional flow of molecules between the 
cytoplasmic and the extracellular space seems to be characteristic for dystrophin-
deficient muscle in vitro and in vivo. This exchange of molecules occurs during 
normal mechanical muscle activity and is aggravated by mechanical stress. 
If we return to the pathophysiology of dystrophin-deficient muscle, the above-
mentioned calcium hypothesis and the leaky membrane hypothesis may be 
integrated to a “mechanical hypothesis.” A higher fragility of the plasma membrane 
during mechanical activity seems to be the direct physiological consequence of the 
lack of dystrophin. This increased fragility results in short-lived membrane lesions 
of limited size, which allow the efflux of cytoplasmic molecules from the cell and 
also the influx of molecules into the sarcoplasm. The efflux of cytoplasmic 
components is probably an indicator of muscle membrane damage rather than of 
great pathophysiological importance. Among the molecules that enter the muscle 
fibers, Ca2+ are thought to be those with the greatest pathogenic consequences 
[176]. Increased influx of Ca2+ into the subsarcolemmal space can lead to the 
activation of degradative enzymes and overload and dysfunction of Ca2+ cycle and 
storage systems. This results in damage of the sarcolemma from interior, 
impairment of mitochondrial function, and modulation of intracellular signaling 
pathways. Because membrane lesions are of limited size in the beginning of the 
necrotic process and Ca2+ is quickly bound by target proteins, the early 
consequences of Ca2+ influx will probably be restricted to the subsarcolemmal 
space of the muscle fibers. A key factor may be an increased calpain activity. 
Possible substrates of calpains are the membrane cytoskeleton, the Ca2+-ATPase 
of the plasma membrane, and ion channel proteins. The Ca2+ pump located in the 
plasma membrane is a preferred substrate of calpain in erythrocytes [201], and if 
attacked in dystrophin-deficient muscle, this calpain action would, in addition to 
provoking an excess of Ca2+ influx, disturb an important extrusion pathway. Using 
immunohistochemical staining, Kumamoto et al. [202] showed an increase in 
calpain especially in the myofibrillar area (Z disks) in atrophic DMD muscle fibers 
but not in morphologically intact fibers. This indicates that an increased calpain 
content of dystrophin-deficient muscle fibers is probably not an early event in the 
dystrophic process. An alternative pathway of cell damage involving mitochondrial 
dysfunction has been suggested for dystrophin-deficient muscle [203, 204]. 
Mitochondrial mRNAs have been found to be downregulated in mdx muscle [205], 
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and a lack of calmitine, a Ca2+-binding protein present in mitochondria, was shown 
in DMD muscle. However, it is not clear whether mitochondrial dysfunction and 
energy depletion are critical and early steps in the dystrophic process. Another 
pathway of Ca2+ influx, in addition to that mediated by membrane lesions, was 
pointed out by Turner et al. [206]. They demonstrated that proteolytic cleavage of 
plasma membrane Ca2+ channels can lead to increased openings of these 
channels [206]. This could mean a loop of positive feedback of Ca2+ influx, Ca2+-
dependent proteolysis, and increased Ca2+ influx.  
Among the Ca2+-related pathways reported to be involved in skeletal myopathies, 
SOCE is probably the most recently discovered. The importance of SOCE in an 
excitable tissue such as skeletal muscle, although previously underappreciated, 
has recently been highlighted by data from mouse models and patients with 
immunodeficiency. Consistent with the proposed role of SOCE in store refilling and 
longterm Ca2+ homeostasis, skeletal muscle isolated from STIM1 deficient mice 
showed reduced tetanic force and fatigued rapidly upon repeated stimulation [207]. 
Moreover, loss of STIM1-dependent SOCE in mice results in a profound myopathy 
and perinatal mortality [207]. Morphologially, the myopathy in Stim1−/− mice is 
characterized by reduced muscle crosssectional area and mitochondriopathy. A 
similar if less pronounced myopathy in mice transgenic for the nonfunctional 
ORAI1-R93W mutant was also observed [208]. Myopathy in ORAI1- and STIM1-
deficient patients becomes apparent soon after birth as global, nonprogressive 
muscular hypotonia with reduced muscle strength and endurance [209]. In ORAI1-
deficient patients, it initially manifested through insufficient head control and 
general reduction in muscle tone [209, 210]. In the two patients surviving after 
HSCT, myopathy is characterized by delayed ambulation, reduced walking 
distance, and a positive Gowers’ sign. In addition, both patients suffer from chronic 
pulmonary disease due to respiratory muscle insufficiency and retention of 
bronchial secretion resulting in a predisposition to recurrent chest infections and 
bronchiectasis [209]. A muscle biopsy from a patient with ORAI1-R91W mutation 
showed variations in muscle fiber size with a predominance of type I fibers and 
atrophic type II fibers suggesting a defect in fast twitch muscle fiber differentiation 
in the absence of functional ORAI1. Other structural abnormalities characteristic of 
congenital myopathies were not observed. A clinically similar nonprogressive 
global muscular hypotonia with partial iris hyoplasia was also observed in all three 
patients lacking STIM1 expression, although a muscle biopsy revealed no 
abnormalities [211]. Electromyograms in both ORAI1- and STIM1- deficient 
patients were normal. These findings suggest that SOCE mediated by ORAI1 and 
STIM1 is required for the differentiation and/or function of human skeletal muscle. 
The myopathy in human patients and gene-targeted mice is consistent with the 
robust expression of both ORAI1 and STIM1 in human and mouse skeletal muscle 
[209, 212-214] and colocalization of STIM1 with ryanodine receptor (RyR) 1 at the 
junction of plasma membrane T-tubules with the terminal cisternae of the 
sarcoplasmic reticulum (SR) [207]. Abnormalities in store operated Ca2+ influx are 
observed in pathologic states such as muscular dystrophy and malignant 
hyperthermia (Fig. 14). The mechanism by which abnormal SOCE contributes to 
the pathogenesis of these disorders is unclear but likely includes activation of 
maladaptive Ca2+ signaling pathways leading to disorders of metabolism, abnormal 
protein handling, and adverse remodeling. 
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Figure 14: Schematic overview of the pathophysiological consequences of 
SOCE dysregulation based on mouse-model studies. 
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MATERIALS AND METHODS 
1. Isolation and characterization of blood-derived CD133+ stem 
cells by flow cytometry 
Circulating CD133+ stem cells were collected from peripheral blood of normal 
subjects and DMD patients. The protocol of cell isolation was previously described 
[50]. After determination of the purity of the CD133+ stem cells, we plated the cells 
in the presence of a proliferation medium (PM) composed of DMEM/F-12 (1:1); 
20% FBS, including Hepes (N-(2-hydroxyethyl)piperazine-N’-(ethanesulfonic acid)) 
buffer (5 mM), glucose (0.6%), sodium bicarbonate (3 mM), and glutamine (2mM); 
SCF (100 ng/ml; TEBU, Frankfurt, Germany); VEGF (50 ng/ml; TEBU, Frankfurt, 
Germany); and LIF (20 ng/ml; R&DSystems, Minneapolis,MN, USA). Cell viability 
assay was performed using 7-Amino-actinomycin D (7-AAD) viability probe. For 
four-color flow cytometric analysis, at least 30 x 104 to 80 x 104 cells were 
incubated with the following monoclonal antibodies (mAbs): anti-CD133/2-
phycoerythrin (PE) (Miltenyi Biotec, Germany), anti-CD34-Allophycocyanin (APC) 
(BD, Franklin Lakes, NJ, USA), anti-CDw90 (Thy-1)-fluorescein-isothiocyanate 
(FITC) (BD, Franklin Lakes, NJ, USA), anti-VEGF-R2 (KDR)-PE (R&D Systems, 
Minneapolis, MN, USA), anti-CD184 (CXCR4, fusin)-PE-Cy5 (BD, Franklin Lakes, 
NJ, USA), anti-CD45-FITC (BD, Franklin Lakes, NJ, USA), and anti-CD20-FITC 
(BD, Franklin Lakes, NJ, USA). For each mAb, an appropriate isotype-matched 
mouse immunoglobulin was used as a control. After staining performed at 4°C for 
20 min, cell suspensions were washed in PBS containing 1% heat inactivated FCS 
and 0.1% sodiumazide. Cells were analyzed using a FACSCalibur flow cytometer 
and PAINT-a Gate software (BD, Franklin Lakes, NJ, USA). The commercially 
available BDKit (BD, Franklin Lakes, NJ, USA) was used to quantify the number of 
CD20+ cells among normal and dystrophic circulating CD133+ stem cells. The 
commercially available Quantibrite™ Beads system (BD, Franklin Lakes,NJ,USA) 
was used to determine the number of CD20 molecules on membrane of normal 
and dystrophic circulating CD133+ stem cells, according to manufacturer’s 
instructions. 
2. Evaluation of dystrophin isoforms expression in CD133+ stem 
cells by RT-PCR and western blot 
Total RNA was extracted from normal and dystrophic circulating CD133+ stem cells 
by TrizolReagent (Invitrogen, Carlsbad, CA, USA). First-strand cDNA was prepared 
by using Super Script First Strand Synthesis System for RT-PCR (Invitrogen, 
Carlsbad, CA, USA), starting from 2 µg total RNA with oligo(dT)12-18 primers. To 
investigate the expression of the most common dystrophin isoforms, we designed 
five different pairs of human-specific primers:  
 
 forward primer reverse primer 
427kD 5’-CCTACAGGACTCAGATCTGG-3’ 5’-GTCCTCTACTTCTTCCCACC-3’ 
260kD 5’-GCATCCAGTCTGCCCAGG-3’ 5’-GAGACAGGACTCTTTGGGCAG-3’ 
140kD 5’-GGATGGCATTGGGCAGCG-3’ 5’-GCTCTTTTCCAGGTTCAAGTGG-3’ 
116kD 5’-CCTCCAAGGTGAAATTGAAGC-3’ 5’-CTGGCTTCCAAATGGGACC-3’ 
71kD 5’-CCACGAGACTCAAACAACTTGC-3’ 5’-CTTGAGGTTGTGCTGGTCC-3’ 
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Map showing the five dystrophin isoforms and the primers used for amplification 
 
The GAPDH gene was amplified as housekeeping using the following couple of 
primers: F(5’-GCACAAGAGGAAGAGAGAGAC-3’) and R(5’-
GATGGTACATGACAAGGTGCGG-3’). PCR was performed under the following 
conditions: 94°C for 5 min, then 35 cycles at 94°C for 40 s, 68°C for 40 s, and 72°C 
for 1 min. cDNA samples obtained from blood-derived CD133+ stem cells cultured 
in proliferative conditions were used, and PCR products were analyzed on 2% 
agarose gels. For Western blot analysis of Dp71, normal and dystrophic circulating 
CD133+ stem cells and CD133- cells were lysed directly in 1X sample buffer (1% 
SDS) containing 2 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mM sodium fluoride 
(NaF), 1 mM sodium vanadate (Na3VO4) and 1 mM phenylmethylsulfonylfluoride 
(PMSF). Lysates were boiled 5 min and centrifuged at 10000 x g for 5 min to 
remove insoluble material. Total protein concentration was determined according to 
Lowry’s method [215] and lysates were stored at -20°C. Samples were analyzed 
on 7.5%polyacrylamide gel, transferred to supported nitrocellulose membranes 
(Bio-Rad Laboratories, Hercules, CA, USA), and the filters were saturated in 
blocking solution (10 mM Tris, pH 7.4, 154 mM NaCl, 1%BSA, 10%horse serum, 
0.075%Tween-20) overnight at 4°C. Primary antibodie s (NCL-Dys2 - Novocastra 
Laboratories, Newcastle, UK; anti-βactin - Sigma, Milan, Italy) were incubated for 
90 min at room temperature and then followed by washing, detection with 
horseradish peroxidase (HRP) conjugated secondary antibodies (DakoCytomation, 
Carpinteria, CA, USA), and developed by enhanced chemiluminescence (ECL) 
(Amersham Biosciences, Piscataway, NJ, USA). Prestained molecular weight 
markers (Bio-Rad Laboratories, Hercules, CA, USA) were run on each gel. Bands 
were visualized by autoradiography using Amersham Hyperfilm™ (Amersham 
Biosciences, Piscataway, NJ, USA). 
3. Immunoprecipitation and western blotting from blood-derived 
CD133+ stem cells 
For the precipitation of CD20 complexes, cells were pelletted at 3000 rpm for 7 min 
at 4°C and then lysed in 1% Nonidet P-40 detergent buffer containing 20mM Tris, 
pH 8, 137 mM NaCl, 2 mM EDTA, 10% glycerol, 2 mg/ml aprotinin, 10 mg/ml 
leupeptin, 10mM NaF, 1mM Na3VO4 and 1mM PMSF. After 15 min on ice with 
occasional agitation, samples were centrifuged at 10000 x g for 10 min at 4°C to 
remove insoluble material. Total protein concentration was determined according to 
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Lowry’s method [215] and lysates were stored at -20°C. Lysates (200-300 mg of 
total proteins) were incubated with 10 mg of anti-CD20 antibody (M-20, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) and mixed overnight at 4°C before 
adding 50 ml of Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA). Beads were incubated for 3h at 4°C and then washed 3 times with 
PBS before addition of 30 ml of 1X sample buffer containing 1% SDS. Samples 
were boiled for 5 min, centrifuged at 10000 x g for 5 min at room temperature and 
supernatants (IP samples) were resolved on 10% polyacrylamide gels. After 
transfer to supported nitrocellulose membranes (Bio-Rad Laboratories, Hercules, 
CA, USA), the filters were processed with the proper antibodies as described 
above. CD20 phopshorylation was assayed using anti-phosphothreonine (H-2, 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-phosphoserine 
(16B4, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) primary antibodies. 
To evaluate Lyn activation after interaction with CD20, filters were incubated with 
specific anti-Lyn antibody (#2732, Cell Signaling Technology, Inc., Danvers, MA, 
USA), then stripped and reprobed with anti-phosphotyrosine antibody (PY99, 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Obtained bands were 
acquired using the Epson Perfection 2400 PHOTO Scanner and the Epson Scan 
Software. Densitometric analysis were performed using ImageJ software 
(http://rsbweb.nih.-gov/ij/).  
4. Measurement of cytoplasmic Ca2+ concentration in blood-
derived CD133+ stem cells 
Measurement of cytoplasmic calcium concentration [Ca2+]i. Cells were suspended 
in a physiological solution (PS) containing NaCl 154 mM, KCl 5 mM, MgCl2 1 mM, 
CaCl2 1.8 mM, Glucose 10 mM, Hepes 10 mM (pH adjusted to 7.4 with NaOH) and 
centrifuged for 4 min at 1500 x g. Cells were loaded with Ca2+ indicators by 
incubation in the PS solution containing the acetoxy methyl ester (AM) of Fura-2 (9 
µM in dimethyl sulfoxide [DMSO]) or Fluo3 (2 mM in DMSO) (Molecular Probes 
Europe, Leiden, The Netherlands), for 45 min at room temperature (20 – 22°C), in 
the dark, with gentle mixing. Cells were then centrifuged, resuspended in PS and 
allowed to complete hydrolysis of AM ester groups for 30 min at room temperature. 
Images were obtained with a fluorescence microscope (Nikon Eclipse 600), using a 
CFI Fluor 60X, 1.0 NA, water-immersion objective. Cells were settled, at low 
density, in a glass imaging chamber. Images were acquired by a CCD camera 
(Panasonic, WV-BP514E) and collected using Axon Imaging Workbench 2.2 
software (Axon Instruments Inc., CA, USA), by averaging 16 frames (time of 
exposure 528 ms). To visualize changes of [Ca2+]i Fluo3 loaded cells were imaged 
at 520 nm by exciting at 480 nm every 5 – 30 seconds to minimize dye 
photobleaching. The fluorescence signals, Fbase and F, were computed as the 
mean pixel value in each region of interest covering a single cell, at the beginning 
and during the time course, respectively. The normalized change in fluorescence 
was reported as a pseudoratio, which is thought to approximately reflect [Ca2+]i and 
was calculated using the equation: ∆F/F = (F-Fbase)/(Fbase-B), where B is the 
background signal averaged over cell free areas. To measure the intracellular free 
Ca2+ levels, Fura-2 loaded cells were alternatively excited at 340 and 380 nm while 
they were imaged at 510 nm at room temperature. After background subtraction, 
ratio images were obtained by dividing pixel by pixel couples of digitized images at 
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340 and 380 nm. In each cell the fluorescence intensity was measured by the 
mean pixel value in a region of interest covering most of the cell area. 
Fluorescence values can be converted into ion concentrations according to the 
equation given by Grynkiewicz and colleagues [216]: [Ca2+] = Kd [(R-Rmin)/(Rmax-R)] 
X (Ff380/Fb380), where R is the ratio of the fluorescence intensities measured at 340 
and 380 nm, Rmin is the limiting value of R when all the indicator is in the Ca2+-free 
form, Rmax when it is saturated with calcium, Kd is the dissociation constant of the 
Fura-2-calcium complex, Ff380 and Fb380 are the fluorescence intensities of Ca2+-
free and Ca2+-bound Fura-2 at 380 nm, respectively. For calibration, Ca2+-saturated 
or Ca2+-free dye can be set by 5 µM ionomycin in the presence of 2.5 mM Ca2+ or 
by 10 mM EGTA (ethyleneglycolbis(ß-aminoethyl ether)N,N-tetraacetic acid) in 
nominally Ca2+-free solution, respectively. Ionomycin was purchased from 
Calbiochem (Inalco, Italy) whilst all other reagents were obtained from Sigma 
(Milan, Italy). We also performed measurements of intracellular calcium on normal 
and dystrophic circulating CD133+ stem cells after stimulation with 100 ng/ml BDNF 
in RPMI 1640 medium (Gibco - Invitrogen, Carlsbad, CA, USA). The cells were 
analyzed 2h after BDNF stimulation. 
5. ELISA assays on cell culture supernatants 
After 24h of culture, media from normal and DMD blood-derived CD133+ stem cells 
were collected and used for ELISA quantification of secreted cytokines. 
Quantikine® Immunoassay (R&D Systems, Minneapolis, MN, USA) specific for 
human IGF-1, VEGF, BDNF and TGFβ-1 were performed according to 
manufacturer’s instructions. Media were added to a 96-well polystyrene microplate 
coated with specific monoclonal antibodies. Secreted cytokine was detected by 
treating the plates with the respective polyclonal or monoclonal HRP conjugated 
detection antibody. Enzyme substrate was added to generate a color product 
whose absorbance was read at 450 nm. A cytokine standard included in each 
assay was used to generate a standard curve that was used to calculate the 
amount of secreted cytokine per well. Samples were assayed in duplicate.  
6. Animal models 
All procedures involving living animals were performed in accordance with Italian 
law (D.L.vo 116/92 and subsequent additions), which conforms to the European 
Union guidelines. Experimental animals were obtained from Charles River Lab-
oratories International, Inc. (Calco, Italy). Normal C57BL and immune-deficient 
SCID mice were used throughout this study. Severe combined immune-deficient 
(SCID) mice are generally devoid of functional B and T lymphocytes [217]; this 
deficit results from highly error-prone recombination of antigen receptor genes 
[218]. All mice were fed ad libitum and allowed continuous access to tap water. 
Animals were deeply anesthetized with 2% avertin (0.015 ml/kg) prior to sacrifice 
by cervical dislocation, and all efforts were made to minimize suffering. 
7. Evaluation of CD20 expression in skeletal muscle by RT-PCR 
Total RNA was extracted from cells, muscles, and single fibers using Trizol 
Reagent (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions.  
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The C2C12 mouse myoblast cell line was commercially obtained from the ATCC 
(number CRL-1772). First-strand cDNA was prepared using the Super Script III 
First Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA), 
starting from 1  µg of total RNA with oligo (dT)12–18 primers. In mouse samples, 
CD20 expression was investigated using the following primer pairs:  
 
 forward primer reverse primer 
F1-R1 5’-AGTTGAATGTAAGAAGCAAGC-3’ 5’-AGCTTATACAGGCATATGGGC- 3’ 
F2-R2 5’-TCTCTAAGCCTCTTTGCTGC-3’ 5’-AAGAAGGCAGAGATCAGCATCG-3’ 
 
The F1–R1 pair aligned in the 3’- UTR, while the F2–R2 pair was directed against 
the ORF (exons 5–6) of murine CD20 mRNA. RNA from C57BL spleen and from 
3T3 fibro-blasts were used as positive and negative controls, respectively. PCR 
conditions were as follows: 92°C for 1 min, 56°C fo r 1 min, and 72°C for 1 min (36 
cycles). The obtained bands were sequenced to check the specificity of PCR 
amplification. The mouse GAPDH gene was amplified as a standard control, using 
the primer pair F (5’-GTGGCAAAGTGGAGATTGTTGCC-3’) and R (5’-GATGAT 
GACCCGTTTGGCTCC-3’) and the following PCR conditions: 92°C for 1 min, 67°C 
for 1 min, and 72°C for 1 min (36 cycles). Human CD 20 mRNA was amplified with 
a primer pair aligning at the 3’-UTR:  
 
 forward primer reverse primer 
Fh-Rh 5’-GCAACAGATGATTCCAACATGGGTG-3’ 5’-ATGACCTGACACCTCACCGTTCAA-3’ 
 
PCR conditions were 94°C for 1 min, 59°C for 1 min,  and 72°C for 1 min (36 
cycles). The human GAPDH gene was amplified using the primer pair F (5’-
GCACAAGAGGAAGAGAGAGACC-3’) and R (5’-
GATGGTACATGACAAGGTGCGG-3’) and the following PCR conditions: 94°C for 
1 min, 67°C for 1 min, and 72°C for 1 min (36 cycle s). All PCR products were 
analyzed on 2% agarose gels. Bands were visualized using the UVIsave Imaging 
System (UVItec Limited, Cambridge, UK).  
8. Evaluation of CD20 expression in skeletal muscle by flow 
cytometry 
About 6–8 x 104 C2C12 myoblasts were incubated with a goat polyclonal antibody 
directed against the extracellular loop of CD20 (anti-CD20 (I-20); Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) (1:50), as well as with a rabbit 
monoclonal antibody directed against the C-terminal region of the protein (anti-
CD20 (C-term); Merck Millipore, Darm-stadt, Germany) (1:20). A mild 
permeabilization (0.2% Tween-20 in PBS) was performed for 15 min at room 
temperature prior to staining cells with the anti-CD20 (C-term) monoclonal 
antibody. After overnight staining at 37°C or 20 mi n of incubation at room 
temperature, cells were washed and exposed to the corresponding secondary 
antibody (Alexa Fluor 647-conjugated chicken anti-goat or Alexa Fluor 488-
conjugated goat anti-rabbit; both from Molecular Probes, Invitrogen, Carlsbad, CA, 
USA) (1:100). Washing was performed to remove unbound secondary antibody, 
and cells were analyzed using a FC500 MCL System with CXP software (Beckman 
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Coulter, Miami, FL, USA). Cells exposed to the appropriate isotype control antibody 
were used as negative controls.  
9. Evaluation of CD20 expression in skeletal muscle by western 
blot 
C2C12 murine myoblasts/myotubes and CHQ human myoblasts were directly 
lysed in 1 x sample buffer (1% SDS) with a commercially available cocktail of 
protease and phosphatase inhibitors (Complete® and PhosSTOP®, respectively; 
both from Roche, Mannheim, Germany). TA, QA, and DIA were removed from 
three-month-old C57BL (n = 3) and SCID (n = 3) mice immediately after death by 
cervical dislocation. Samples dedicated to whole muscle analysis were snap-frozen 
in liquid nitrogen and stored at −80°C until proces sed for total protein extraction. 
Samples dedicated to single fiber isolation were placed in 35-mm dishes containing 
DMEM HG (EuroClone, Pero, Italy) and exposed to a mild enzymatic digestion with 
1.4% trypsin (Gibco-Invitrogen, Carlsbad, CA, USA) at 37°C. After 10 min, trypsin 
activity was blocked by transferring muscles into serum containing DMEM with 
15% FBS (Invitrogen, Carlsbad, CA, USA), and fibers were mechanically dissected 
under an optical microscope (Zeiss) until vascular, connective, and adipose tissues 
were completely removed. For total protein extraction, muscles were homogenized 
using an electric homogenizer with a 1% Nonidet P-40 detergent buffer containing 
20 mM Tris (pH 8), 137 mM NaCl, 2 mM EDTA, 10% glycerol, and the Complete® 
and PhosSTOP® cocktails. Similarly, single fibers were homogenized with an 
electric homogenizer directly in 1 x sample buffer (1% SDS) with Complete® and 
PhosSTOP® cocktails. Total protein concen-tration was determined according to 
Lowry’s method [215]. Samples were resolved on 12% polyacrylamide gel, 
transferred to supported nitrocellulose membranes (Bio-Rad Laboratories, Her-
cules, CA, USA), and the filters were saturated in blocking solution (10 mM Tris 
(pH 7.4), 154 mM NaCl, 1% BSA, 10% horse serum, and 0.075% Tween-20). The 
anti-CD20 (M-20), a goat polyclonal directed against the C-terminal region of CD20 
(1:200), and the anti-GAPDH (V-18) (1:1000) (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA) antibodies were incubated for 90 min at room temperature, 
while the anti-CD20 (C-term) monoclonal antibody (1:500) was incubated overnight 
at 4°C. Detection was performed with horseradish pe roxidase (HRP)-conjugated 
secondary antibodies (DakoCytomation, Carpinteria, CA, USA), followed by 
enhanced chemiluminescence (ECL) development (Amersham Biosciences, 
Piscataway, NJ, USA). Prestained molecular weight markers (Bio- Rad 
Laboratories, Hercules, CA, USA) were run on each gel. Bands were visualized by 
autoradiography using Amersham HyperfilmTM. Images of bands were obtained 
using the CanoScan LiDE60 Scanner (Canon) and the Canon ScanGear Software. 
Densitometric analyses were performed using ImageJ software 
(http://rsbweb.nih.gov/ij/). To verify the ability of the anti-CD20 (M-20) antibody to 
recognize its specific target, positive sources of CD20 and C2C12 myoblasts were 
stained after antibody pre-incubation with a specific blocking peptide to compete 
the signal (antibody:peptide 1:1, overnight at 4 ◦C) (CD20 (M-20) blocking peptide) 
(0.2 µg/µl).  
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10. Analysis of CD20 localization in skeletal muscle by 
immunofluorescence 
C2C12 myoblasts, C2C12-derived myotubes, and a series of 10 µm transverse 
cryosections from TA and QA of C57BL and SCID mice were examined by 
immunofluorescence staining. CD20 was detected with anti-CD20 (M-20) (1:20) 
and anti-CD20 (C-term) (1:100) antibodies. To verify the ability of the anti-CD20 
(M-20) antibody to recognize its specific target, a positive source of CD20 (spleen 
cryosections from C57BL mice) was stained after anti-body pre-incubation with a 
specific blocking peptide to compete the signal (antibody:peptide 1:1, overnight at 
4 ◦C) (CD20 (M-20) blocking peptide; Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA) (0.2 µg/µl). Laminin was stained using a rabbit polyclonal antibody from 
Sigma (Milan, Italy) (1:100). α-sarcoglycan was stained using a mouse monoclonal 
antibody from Novocastra Laboratories (Newcastle Upon Tyne, UK) (1:50). Nuclei 
were stained with DAPI. Alexa Fluor 488- and Alexa Fluor 594-conjugated 
secondary antibodies (1:100) were used. Images were captured using the Leica 
TCS SP2 confocal system equipped with a 63x/1.40–0.60 objective (Leica, 
Germany). 
11. Preparation of skeletal muscle sarcolemma 
Portions of skeletal muscle were thawed in 0.9% saline, then quickly trimmed of 
any adhering skin, nerves, fat, or connective tissue, and weighed. Individual 
sarcolemma fractions were prepared from 0.5 to 2 g portions of skeletal muscle. 
The isolation procedure was based on that of Severson et al. [219]. Each trimmed 
0.5 to 2 g portion of skeletal muscle was transferred to a 50-ml glass beaker to 
which 10 ml of 50 mM CaCl2 was added. The muscle was minced finely with 
stainless steel scissors and then homogenized on ice with an Ultraturrax 
homogenizer, applying three 15-s bursts with a 30-s rest between each. This 
homogenate was filtered, through two layers of cheesecloth to remove residual 
connective tissue, into a 50-ml plastic centrifuge tube and centrifuged at 3000 x g 
in a Sorvall centrifuge (model RC5C, rotor SS34) at 4°C for 10 min. The 
supernatant was poured off, and 10 ml of 10 mM Tris–Cl (pH 8.0) was added to the 
pellet. The pellet was re-suspended using a Teflon pestle with 20 non-shearing 
strokes (up + down = 1). After wash, the pestle was rinsed with 5 ml of buffer to 
guard against loss of material. The suspension was then centrifuged again and the 
supernatant discarded. The pellet was washed and centrifuged twice more, in the 
same manner. The third and final supernatant was discarded. To the final pellet, 10 
mM Tris–Cl (pH 8.0) was added at 4 ml/g of trimmed skeletal muscle. The pellet 
was then re-suspended using 20 strokes of the teflon pestle, as previously 
described, and the suspension was transferred to a 25-ml glass beaker containing 
a teflon-coated magnet. Each beaker was cov-ered with parafilm and stored at 4°C 
overnight. The next day, the suspensions were stirred magnetically, while 50 mM 
lithium bromide (LiBr) was added, drop by drop, to a total concentration of 0.2 ml 
per 10 ml suspension. Stirring was continued for 3h to effect extraction of 
contractile elements. The LiBr-extracted suspension was then transferred to a 50-
ml plastic centrifuge tube, 20 ml of 10 mM Tris–Cl (pH 8.0) was added, and the 
mixture was centrifuged at 10000 x g in a Sorvall centrifuge at 4°C for 10 min. The 
supernatant was poured off and the pellet was re-suspended with 10 ml of 10 mM 
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Tris–Cl (pH 8.0) using 20 strokes of the teflon pestle, effectively washing the pellet. 
The re-suspended washed pellet was centrifuged at 6000 x g at 4°C for 10 min and 
the supernatant was discarded. To the pellet, 25% potassium bromide (KBr) was 
added (4 ml/g of trimmed muscle) and the pellet was resuspended using 20 strokes 
of the teflon pestle, followed by centrifugation at 10000 x g in the Sorvall centrifuge 
at 4°C for 30 min. The KBr-treated pellet was washe d once with 10 mM Tris–Cl (pH 
7.5) to remove residual KBr, using 20 strokes of the teflon pestle, and was 
centrifuged at 6000 x g at 4°C for 10 min. The supe rnatant was discarded, and the 
final pellet was re-suspended in 200 µl of 1 x sample buffer containing 2% SDS, 
and boiled for 10 min. Isolated sarcolemma samples were stored at −20°C until 
analysis.  
12. Immunoprecipitation of CD20 from myoblasts and skeletal 
muscle tissue 
Total protein extracts from C2C12 murine myoblasts, C57BL QA, SCID QA, and 
human muscular tissue were prepared in 1% Nonidet P-40 detergent buffer 
containing 20 mM Tris (pH 8), 137 mM NaCl, 2 mM EDTA, 10% glycerol, and 
Complete® and PhosSTOP® cock-tails. Total protein lysates (1000–1500 µg) were 
pre-cleared for 4h at 4°C by adding 50 µl of Protei n A/G PLUS-Agarose (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Pre-cleared lysates were then 
incubated with 10–15 µg of anti-CD20 (M-20) antibody and mixed overnight at 4°C 
before adding 50 µl of Protein A/G PLUS-Agarose. Beads were incubated for 4h at 
4°C, then washed 5 times with PBS; 1 x sample buffe r containing 1% SDS was 
added and the samples were boiled. Next, samples were centrifuged at 10000 x g 
for 5 min, and supernatants (IP samples) were collected. Proteins that were non-
specifically adsorbed by beads were extracted with the same procedure at the end 
of the pre-clearing step and used as a control of IP specificity.  
13. Mass spectrometry 
MALDI-TOF analysis was carried out on CD20 IPs from C2C12 myoblasts and QA 
muscles (C57BL or SCID mice). Following monoD-electrophoresis, anti-CD20 
stained bands that were also appreciable in silver-stained paired lanes from the 
same gel were recovered and processed for MS analysis. Each band was excised, 
cut in small pieces, and dried in a Speed Vac. The gels were soaked with 
ammonium bicarbonate 0.1 M and digested overnight with sequencing grade 
trypsin (Roche, Monza, Italy) at 37°C. The in-gel t ryptic digest was extracted with 
30 µl of 5% HCOOH:CH3CN (1:1) and the peptide mixture was subjected to 
MALDI-TOF analysis using a Bruker Daltonics Reflex IV instrument (Bruker 
Daltonics, Milan, Italy) equipped with a nitrogen laser (337 nm) and operated in 
reflectron mode with a matrix of  α-ciano-4-hydroxy-cinnamic acid in 0.1% 
TFA:CH3CN (2:1). A 2 µl mixture (1:1) of matrix solution and sample was applied to 
the sample plate and air-dried at ambient temperature. External standards were 
used for calibration (Bruker peptide calibration standard). Each spectrum was 
accumulated for at least 200 laser shots. Measured peptide masses were used to 
search the Swiss-Prot, MSDB, TrEMBL, and NCBI sequence databases for protein 
identifications by the Mascot program (http://www.matrixscience.com).  
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14. MTT assay 
To assess the effects of CD20 targeting on cell proliferation, C2C12 myoblasts 
were plated at 2 x 104 cells per 24-well tissue culture plate. The medium was 
replaced at 24h after seeding with fresh medium containing 4 or 20  µg/ml anti-
CD20 (I-20) antibody. After 2h or overnight incubation, cell growth was measured 
using a standard MTT assay (Cell Proliferation Kit I; Roche, Monza, Italy) 
according to the instruction manual. Cells killed by exposure to distilled water were 
used as negative controls.  
15. Apoptotic assay 
For quantification of apoptotic death, C2C12 myoblasts were plated at 6–8 x 104 
cells per 12-well tissue culture plate and treated for 2h or overnight with 4 µg/ml 
anti-CD20 (I-20) antibody. Next, cells were collected and stained with Annexin V 
and propidium iodide using the AnnexinV-FITC Apoptosis Detection Kit (Bender 
MedSystems, Wien, Austria) essentially following the instructions of the 
manufacturer. Samples were analyzed on a FC500 MCL Sys-tem with CXP 
software.  
16. CD20 gene silencing 
To obtain CD20-silenced C2C12 myoblasts, we used commercially available 
lentiviral particles containing three target-specific constructs that encode 19- to 25-
nt (plus hairpin) shRNA designed to knock down CD20 mRNA (CD20 shRNA (m); 
Lentiviral Parti-cles, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Briefly, 
cells were plated at 104 cells per 48-well tissue culture plate, and 105 infectious 
units of virus were added to the culture medium (MOI = 10). The medium was 
replaced 24 h after infection, and infected cells were selected with puromycin (1–2 
µg/ml) (Sigma, Milan, Italy) for 3 weeks. Using the same procedure, we also pre-
pared C2C12 myoblasts infected with an shRNA construct encoding a scrambled 
sequence that will not lead to the specific degradation of any known cellular mRNA 
(Control shRNA; Lentiviral Particles, Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA), for use as controls. As described above, semi-quantitative RT-PCR and 
WB were performed on puromycin-selected cells to monitor CD20 expression 
knock down.  
17. Quantitative evaluation of intracellular Ca2+ dynamics in 
skeletal myoblasts 
Normal or silenced C2C12 myoblasts were cultured for 24–36h before measuring 
store-operated Ca2+ entry. Cells receiving antibody treatment were incubated 
overnight with 4 µg/ml anti-CD20 (I-20) or anti-FLAG (used as control) (Sigma-
Aldrich; Italy). Cultures were loaded for 45 min at 37°C with 1  µM Fura-2-AM (Life 
Technologies, Italy) in Krebs–Ringer solution buffered with HEPES, 125 mM NaCl, 
5 mM KCl, 1.2 mM MgSO4, 2 mM CaCl2, 10 mM glucose, and 25 mM HEPES (pH 
7.4), and were washed twice with pre-warmed calcium free Krebs–Ringer solution 
before recordings were made. Cells were recorded in calcium free Krebs–Ringer 
solution added with 500 µM EGTA (Sigma–Aldrich; Italy), then exposed to 10 µM 
thapsigargin (Sigma–Aldrich; Italy). Following cell response, 2 mM CaCl2 was 
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added to the solution and SOCE response was recorded. The recording setting 
comprised an inverted microscope (Leica, DMI600B) equipped with a Ca2+ imaging 
unit. Polychrome IV (TILL Photonics; Germany) was used as a light source. Fura-2 
fluorescence images were collected with a Andor CCD Camera (Axon Instruments, 
CA, USA) and analyzed with Imaging WorkBench 6 (INDEC BioSystem, Santa 
Clara USA). Single-cell 340/380 nm fluorescence ratios were analyzed with Origin 
6.0 (Microcal Software Inc., MA, USA).  
18. Statistics 
Values are expressed as mean ± SEM. Statistical comparison among three or 
more groups was conducted using one-way ANOVA, followed by Bonferroni’s 
multiple comparison test to determine significance (*P < 0.05, **P < 0.01, ***P < 
0.001). Otherwise, Student’s t-test was applied.  
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RESULTS 
1. CD20-related pathway affecting intracellular Ca2+ is differently 
activated in dystrophic circulating progenitors retaining  
myogenic potential 
The myogenic capacity of human blood-derived progenitors expressing the CD133 
surface marker was previously described [50, 220]. However, the conditions of 
calcium-release and the role of SOCCs in these cells are not known. The 
extensively reported impairment of Ca2+ homeostasis affecting dystrophic muscular 
cells, together with its central role in all living cells physiology, prompted us to focus 
our efforts on the evaluation of calcium handling in normal and dystrophic blood-
derived CD133+ stem cells and, eventually, on the molecular characterization of 
highlighted differences. 
1.1 Immunophenotyping of blood-derived CD133+ stem cells 
Surface antigens expressed by normal and dystrophic circulating CD133+ stem 
cells were characterized by means of flow cytometry analysis. Hoechst 33342 
staining did not reveal the presence of Side Population (SP) fraction among 
isolated CD133+ cells (99% ± 1% [mean ± SD])(data not shown), moreover up to 
98% of blood-derived CD133+ stem cells showed a lin- phenotype (CD4- CD8- CD3- 
CD19- CD33- CD38-) (data not shown). Normal and dystrophic circulating CD133+ 
stem cells represented less than 0.2% (range 0.04 ± 0.1%, n = 12 normal blood; 
range 0.06 – 0.2%, n = 33 DMD blood) of total blood mononucleated cells as 
previously described [50]. Interestingly, normal and dystrophic circulating CD133+ 
stem cells co-expressed the B-cell marker CD20 (Fig. 1A). More than 92% of 
normal and dystrophic circulating CD133+CD20+ cells also co-expressed CXCR4 
and CD34 antigens (Fig. 1A). By FACS analysis, the percentage of CD133+ stem 
cells expressing the CD20 antigen was not statistically significantly higher in the 
DMD subpopulation than the normal counterpart (27.9% ± 11% vs. 30.1% ± 13.1%; 
p>0.5) (Fig. 1A). Moreover, two subpopulations within the circulating 
CD133+CD20+ cells were observed distinguishing the CD133+CD20bright (1.7 ± 2.1 
and 2.1 ± 1.5 cells/ml from normal and dystrophic blood samples, respectively; 
p>0.5) and the CD133+CD20dim (0.8 ± 0.3 vs. 1.1 ± 0.5 cells/ml; from normal and 
dystrophic blood samples, respectively; p>0.5) (Fig. 1B). In order to quantify the 
number of CD20 molecules on the circulating CD133+CD20+ cells we used the 
Quantibrite™ Beads system. By this method we found no significant differences 
between the number of CD20 antigens expressed in normal and dystrophic 
CD133+CD20bright (27780 ± 12681 vs. 31419 ± 18112 antibody bound per cell, 
ABC; p>0.5) and CD133+CD20dim (1307 ± 491 vs. 1469 ± 1023 antibody bound per 
cell, ABC; p>0.5) (Fig. 1C). These results demonstrate that the percentage of 
circulating CD133+CD20+ cells and the number of CD20 molecules expressed on 
the cell membrane is similar in normal and dystrophic specimens.  
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Figure 1: Characterization of blood-derived CD133+ stem cells 
immunophenotype. (A) FACS immunophenotyping of the fractionated normal 
(lane CTR) and dystrophic (lane DMD) circulating CD133+ stem cells. Normal and 
dystrophic circulating CD133+ stem cells coexpressed the B-cell marker CD20, and 
more than 92% of normal and dystrophic circulating CD133+CD20+ cells also co-
expressed CXCR4 and CD34 antigens. (B) The BDKit analysis allowed us to 
identify two subpopulations within the circulating CD133+ stem cells distinguishing 
the CD133+CD20bright and the CD133+CD20dim. (C) The BD Quantibrite™ Beads 
system was used to quantify the number of CD20 molecules on the circulating 
CD133+CD20+ cells. No significant differences were found in the number of CD20 
antigens expressed by normal and dystrophic CD133+CD20bright and 
CD133+CD20dim. (D) Immunoblotting results showed an increased phosphorylation 
of CD20 on threonine residues in dystrophic circulating CD133+ stem cells (lane 
DMD)in comparison to the normal counterpart (lane CTR). 
1.2 CD20 phosphorylation is enhanced in dystrophic blood-derived 
CD133+ stem cells 
To test whether the unexpected expression of CD20 antigen in the circulating 
normal and dystrophic CD133+ stem cells could be related to a possible functional 
pathway, we decided to look at its phosphorylation state by performing 
immunoprecipitation experiments followed by Western blotting. No tyrosine 
residues or recognized signaling motifs occur in any of the cytoplasmic regions of 
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CD20, although there are a number of consensus sites for serine or threonine 
phosphorylation [138]. CD20 was immunoprecipitated from normal and dystrophic 
circulating CD133+ stem cells, separated by SDS-PAGE, transferred to membranes 
and probed with anti-phosphoserine or anti-phosphothreonine antibody. No 
difference was observed concerning serine phosphorylation between normal and 
dystrophic circulating CD133+ stem cells (data not shown), while CD20 showed a 
higher threonine phosphorylation in dystrophic circulating CD133+ stem cells (Fig. 
1D). Taken together these observations supported the state of activation of the 
CD20 antigen, particularly in dystrophic circulating CD133+ stem cells.  
1.3 Impairment of calcium homeostasis in dystrophic blood-derived 
CD133+ stem cells 
Since CD20 expression and its phosphorylation state in circulating CD133+ stem 
cells could be involved in the regulation of the calcium homeostasis [135-138], we 
first performed measurements of [Ca2+]i on normal and dystrophic blood-derived 
CD133+ stem cells. In these experiments, we evaluated the number of cells 
displaying a concentration of cytosolic free calcium to be higher than a reference 
value of 100 nM. In order to quantify the intracellular calcium, we used the dual 
wavelength ratiometric dye Fura-2. In this experiment, we found a significantly 
higher percentage of cells exceeding this reference value in dystrophic circulating 
CD133+ stem cells compared to the normal counterpart (p<0.001) (Fig. 2A). We 
also noted that dystrophic circulating CD133+CD20+ cells displayed a higher 
susceptibility than their normal counterparts to increase [Ca2+]i in response to both 
high [K]o (100 mM) and ionomycin (1 mM) (Fig. 2B). This feature was not further 
studied. However, these data suggest an impairment of Ca2+ homeostasis in the 
circulating dystrophic CD133+CD20+ cells. 
 
 
Figure 2: Evaluation of intracellular free Ca2+ in normal and DMD blood-
derived CD133+ stem cells. (A) The number of normal and dystrophic blood-
derived CD133+ stem cells displaying an [Ca2+]i exceeding the reference value of 
100 nM was quantified and expressed as percentage (%) of the total cells 
analyzed. The number of cells with high [Ca2+]i was significantly higher in DMD 
blood-derived CD133+ stem cells than in normal counterpart (p<0.001). (B) 
Illustrates the time course of the change in the Fluo3 emission in normal (left side) 
and dystrophic (right side) circulating CD133+CD20+ cells, induced by raising the 
extracellular KCl concentration from 5 to 100mM and then applying calcium 
ionophore during the early response steady state. [Ca2+]i increase, measured as 
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pseudoratio (∆F/F%), was abnormally high in dystrophic circulating CD133+CD20+ 
cells. 
1.4 Abnormal BDNF release from dystrophic blood-derived CD133+ 
stem cells 
Since no natural agonist for CD20 has been identified until now, we considered the 
possibility that CD20 channel and/or signal transduction activity can be indirectly 
activated by cytokines or growth factors after interaction with their own receptors 
and consequent activation of intracellular signaling cascades. Following this 
hypothesis, we decided to perform an ELISA screening, looking for released 
factors over-expressed by dystrophic circulating CD133+ stem cells. Supernatants 
were collected after 24 h of culture and the concentrations of IGF-1, VEGF, BDNF 
and TGFβ-1 were measured. Results are expressed as a ratio concentration/cell 
number in culture. While IGF-1 and VEGF were detected in similar amounts in 
normal and dystrophic circulating CD133+ stem cell supernatants (IGF-1: 1.1 x 10–7 
normal vs. 1.8 x 10–7 dystrophic) (Fig. 3A); (VEGF: 2.0 x 10–3 normal vs. -8.5 x 10–4 
dystrophic) (Fig. 3B), BDNF and TGFβ-1 displayed a different release profile 
comparing healthy and dystrophic circulating CD133+ stem cells. BDNF 
measurement in dystrophic blood derived CD133+ stem cell supernatant returned a 
ratio that was six-fold increased in comparison to that obtained from normal cells 
(1.5 x 10–4 normal vs. 6.1 x 10–4 dystrophic; p<0.05) (Fig.3C). A similar trend was 
observed considering TGF-β1, with a ratio of 5.8 x 10–3 in normal circulating 
CD133+ stem cells that increased to a value of 2.6 x 10–2 in dystrophic circulating 
CD133+ stem cells (p<0.05, Fig. 3D). In order to verify whether the increased ratio 
obtained after BDNF and TGFβ-1 dosage in DMD supernatants was a CD133+ 
stem cells specific feature, we performed the same measurements on normal and 
dystrophic CD133- cells. Even with no significant difference, TGFβ-1 ratio showed 
the same increasing trend observed in dystrophic circulating CD133+ stem cells 
(Fig. 3F). On the contrary, the ratio obtained after BDNF dosage was similar 
comparing normal and dystrophic CD133- cells (Fig. 3E). Reported data clearly 
describe two different phenomena: 1) a generalized TGFβ-1 over-expression 
affecting dystrophic circulating cells, with no difference between CD133 positive 
and negative fractions; 2) a BDNF over-expression that specifically affects 
dystrophic circulating CD133+ stem cells, thus promoting this cytokine as a 
possible candidate for the indirect modulation of CD20 phosphorylation and 
signaling activity. 
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Figure 3: ELISA quantification of cytokines release by normal and DMD 
blood-derived CD133+ stem cells. (A and B) IGF-1 and VEGF were detected in 
similar amounts in normal and dystrophic circulating CD133+ stem cell 
supernatants. (C) BDNF measurement in dystrophic blood-derived CD133+ stem 
cell supernatant returned a ratio that was six-fold increased in comparison to that 
obtained from normal cells. (D) A similar trend was observed considering TGF-β1. 
(E and F) Measurements performed on normal and dystrophic CD133- cell 
supernatants allowed to identify BDNF over-expression as an exclusive property of 
dystrophic circulating CD133+ stem cells. On the contrary, TGF-β1 over-expression 
affects dystrophic cells with no difference between CD133 positive and negative 
fractions. 
1.5 BDNF induces CD20-related intracellular signaling activation in 
dystrophic blood-derived CD133+ stem cells 
Since all the functions of BDNF are mediated by the TrkB pathway, including the 
protein kinase C (PKC), an enzyme involved in CD20 phosphorylation [134, 221-
223], we investigated the role of BDNF in CD20 phosphorylation and signaling 
modulation. We first decided to evaluate the effect of BDNF on CD20 
phosphorylation performing immunoprecipitation and Western blotting experiments. 
Normal and dystrophic circulating CD133+ stem cells were stimulated with BDNF 
(100 ng/ml for 2h) and CD20 immunoprecipitation was performed on cell lysates 
followed by phosphothreonine immunoblotting. After BDNF treatment, a strong 
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induction of CD20 phosphorylation was observed both in normal and dystrophic 
blood-derived CD133+ stem cells (Fig. 4A). Moreover, in dystrophic circulating 
CD133+ stem cells CD20 was heavily threonine-phosphorylated also in basal 
condition, probably as a consequence of the higher BDNF release described above 
(Fig. 4A). Tyrosine kinases can associate with the cytoplasmic regions of cell-
surface molecules by different mechanisms, promoting intracellular signaling 
transduction. Previous studies reported CD20-specific association with src-family 
members Lyn, Fyn and Lck, along with a tyrosine phosphorylated protein (p75/80) 
later identified as PAG, a ubiquitous adaptor protein [138, 224, 225]. Importantly, it 
is possible that changes in either the conformation of CD20 or its phosphorylation 
state, or both, could regulate its association with such kinases. To determine 
whether or not BDNF induced phosphorylation is followed by the activation of 
CD20-related downstream signaling pathway, we performed experiments in order 
to analyze CD20-recruited src kinases and their activation state. Considering that 
Lyn accounted for most of the protein tyrosine kinase (PTK) activity in the CD20 
complex [224], we focused our attention on this src-family member. Immune 
complexes were prepared from lysates of normal and dystrophic circulating 
CD133+ stem cells using anti-CD20 antibody. After SDS-PAGE separation, 
membranes were blotted with anti-Lyn antibody, then stripped and re-probed for 
the evaluation of tyrosine phopshorylation. Densitometric analysis performed on 
obtained bands showed that, although Lyn was co-immunoprecipitated with CD20 
in all the conditions tested, after BDNF stimulation CD20 immune complexes 
contained a higher Lyn content both in normal and dystrophic circulating CD133+ 
stem cells, suggesting an induction of Lyn-CD20 interaction after BDNF exposure 
(Fig. 4B). Particularly, even if CD20-recruited Lyn was higher in dystrophic 
unstimulated blood-derived CD133+ stem cells in comparison to normal 
unstimulated bloodderived CD133+ stem cells (threefold increase), the effects 
promoted by BDNF on Lyn association to CD20 were more consistent in dystrophic 
circulating CD133+ stem cells (+43%) than in normal circulating CD133+ stem cells 
(+30%) (Fig. 4C). Membrane reprobing with anti-phosphotyrosine antibody allowed 
us to analyze the activation state of CD20-recruited Lyn. After BDNF treatment, 
only dystrophic circulating CD133+ stem cells showed phosphorylation increase in 
the Lyn fraction co-immunoprecipitated with CD20 (Fig. 4D). As a consequence, 
the ratio phopsho/total protein decreased differently in normal (–29%) and 
dystrophic circulating CD133+ stem cells (–9%) (Fig. 4E). Together, these results 
demonstrate that CD20-related signaling can be indirectly modulated by BDNF. 
Interestingly, effects on CD20 threonine phosphorylation and Lyn recruitment were 
observed, even if with different intensity, both in normal and dystrophic circulating 
CD133+ stem cells. On the contrary, only in dystrophic blood-derived CD133+ stem 
cells does recruited Lyn undergo phosphorylation after BDNF treatment, possibly 
promoting the activation of additional intracellular pathways that can act 
synergically with TrkB. 
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1.6 BDNF induces a different increase of intracellular Ca2+ levels in 
normal and dystrophic blood-derived CD133+ stem cells 
Differences concerning the activation of CD20-recruited Lyn after BDNF 
stimulation, observed while comparing normal and dystrophic circulating CD133+ 
stem cells, invited us to consider the effects on cytosolic Ca2+ promoted by a 
potential simultaneous activation of TrkB and CD20-Lyn pathways in dystrophic 
circulating CD133+ stem cells. As previously described, once activated, TrkB can 
drive intracellular Ca2+ release by means of PLCγ activation and consequent 
production of the second messenger IP3. Lyn activation triggers a cascade of 
signaling events mediated by Lyn phosphorylation of tyrosine residues within the 
immunoreceptor tyrosine-based activation motifs of receptor proteins, and 
subsequent recruitment and activation of other kinases, PLCγ2 and 
phosphoinositide 3-kinase (PI3-K) [226]. These kinases provide activation signals 
that play critical roles in proliferation, cell differentiation and Ca2+ mobilization. 
Since in normal cells Lyn is recruited by CD20 but fails to become phosphorylated, 
the synergic action between the two pathways after BDNF exposure could take 
place only in dystrophic circulating CD133+ stem cells, where a more intense 
increase of [Ca2+]i is thus expected. To assess this hypothesis, we performed 
experiments for the quantification of intracellular free Ca2+ in normal and dystrophic 
circulating CD133+ stem cells in the unstimulated condition (basal) and after BDNF 
treatment. In normal circulating CD133+ stem cells we found that BDNF was able to 
induce an increase in [Ca2+]i that, even if appreciable, was not significant when 
compared to cells analyzed in basal condition (p=0.122) (Fig. 4F). In contrast, 
calcium measurements performed on dystrophic circulating CD133+ stem cells 
showed a significant increase between basal and BDNF treated cells (p<0.001) 
(Fig. 4F). Moreover, the observed intracellular Ca2+ increase was much higher in 
comparison to that obtained in normal circulating CD133+ stem cells subjected to 
identical treatment (Fig. 4F). Data reported here describe a different response to 
BDNF in normal and dystrophic circulating CD133+ stem cells in terms of 
intracellular calcium release, reflecting the fact that only in dystrophic circulating 
CD133+ stem cells does the CD20-Lyn pathway undergo activation after BDNF 
exposure, leading to the supplementary calcium release observed. 
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Figure 4: BDNF modulation of CD20-related signaling pathway. (A) Induction 
of CD20 phosphorylation by BDNF in normal and dystrophic blood-derived CD133+ 
stem cell. In dystrophic circulating CD133+ stem cells CD20 was heavily threonine-
phosphorylated also in basal condition. (B) After BDNF stimulation CD20 immune 
complexes contained a higher Lyn content both in normal and dystrophic 
circulating CD133+ stem cells, suggesting an induction of Lyn-CD20 interaction. (C) 
The effects promoted by BDNF on Lyn association to CD20 were more consistent 
in dystrophic (+43%) than in normal circulating CD133+ (+30%). (D and E) Only 
dystrophic circulating CD133+ stem cells showed a phosphorylation increase in the 
Lyn fraction co-immunoprecipitated with CD20 after exposure to BDNF. As a 
consequence, the ratio phopsho/total protein decreased differently in normal (–
29%) and dystrophic circulating CD133+ stem cells (–9%). (F) Calcium 
measurements performed on dystrophic circulating CD133+ stem cells showed a 
significant increase between basal and BDNF treated cells (p<0.001). Such 
increase was much higher in comparison to that obtained in normal circulating 
CD133+ stem cells subjected to identical treatment. Data were collected from 2070 
basal CTR, 2080 basal DMD, 2668 BDNF CTR and 2118 BDNF DMD cells. The 
differences marked by an asterisk are statistically significant (p<0.001 ANOVA). 
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1.7 Blood-derived CD133+ stem cells express the Dp71 dystrophin 
isoform 
Total mRNA was collected and analyzed by RT-PCR. Normal blood-derived 
CD133+ stem cells expressed the mRNA of the ubiquitous 71 kDa dystrophin 
isoform (Fig. 5A). No expression of the 116-kD, 140-kD, 260-kD and 427 kDa 
dystrophin isoforms mRNA was observed in these cells (Fig. 5A). On the contrary, 
although the DMD genotypes analyzed (∆11–13; ∆26– 30; ∆45– 52; ∆4-6-8-12-13; 
∆17–44; ∆42– 51; ∆43– 45; ∆49– 52; exon 2 duplication) were formally compatible 
with the expression of Dp71, all the dystrophin isoforms mRNA were absent in 
dystrophic circulating CD133+ stem cells, including the Dp71 (Fig. 5A). As 
expected, the Western blot analysis confirmed the expression of the Dp71 
dystrophin isoform only in the normal blood-derived CD133+ stem cells (Fig. 5B). 
Importantly, neither normal nor dystrophic circulating CD133- cells expressed the 
Dp71 dystrophin isoform (Fig. 5B), demonstrating that the expression of Dp71 is a 
CD133+ stem cells specific feature. 
 
 
Figure 5: Dp71 expression by circulating CD133+ stem cells. (A) PCR results 
from normal and dystrophic blood-derived CD133+ stem cells after seven days of 
culture in proliferation (stem-cell-conditioned) media. The first five gels correspond 
to the expression of the different dystrophin isoforms indicated in (A). Last gel 
corresponds to the amplification of the GAPDH gene as standard (PCR fragment 
150 bp). Only the Dp71 mRNA is expressed by normal circulating CD133+ stem 
cells in these conditions (PCR fragment 193 bp). (Size Marker, SM). (B) 
Immunoblotting analysis confirmed that only normal blood derived CD133+ stem 
cells are able to express the Dp71 dystrophin isoform also at protein level (lane 
CD133+ CTR). Neither normal nor dystrophic CD133- cells expressed the Dp71 at 
protein level (lanes CD133- DMD and CD133- CTR). Mouse brain homogenate was 
used as control. β-actin immunoblotting indicated that the same protein 
concentration was present in all specimens. 
A 
B 
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2. CD20 is expressed in skeletal myoblasts and contributes to 
calcium handling by modulating SOCE 
Different studies showed that CD20 can associate with lipid raft domains of the 
plasma membrane, where it is probably involved in store-operated Ca2+ entry 
(SOCE) [139, 140]. The main actors of this process have been identified [110, 111, 
117, 119, 133]; however, there are still several important unresolved issues 
regarding SOCE in skeletal muscle, including the identification of mechanisms and 
molecules involved in the fine regulation of this crucial pathway. The possible 
contribution of CD20 to the regulation of Ca2+ handling in skeletal muscle is an 
important point to address, especially considering that circulating CD133+ 
progenitors and committed muscular cells share common mesodermic origins. 
Human muscle biopsies for research purposes are not easy to obtain, particularly 
from DMD patients. Accordingly, we started to evaluate the expression and the role 
of CD20 as a mediator/modulator of SOCE in C2C12 murine skeletal myoblasts 
cell line. 
2.1 CD20 mRNA is detected in myoblasts and mature muscle fibers 
To investigate CD20 expression in C2C12 myoblasts, we first assayed for the 
presence of CD20 mRNA by RT-PCR analysis. Total RNA was collected and 
analyzed using two pairs of specific primers, one directed against the 3’-UTR (F1–
R1) and one targeting the ORF (F2–R2). CD20 transcript was clearly detectable in 
growing C2C12 myoblasts, and its expression was maintained after 10 days of 
differentiation (myotubes) (Fig. 6A). To evaluate CD20 expression in mature fibers, 
we analyzed three muscle types that differ in myosin heavy chain isoform content, 
anatomical localization, and function-ality. CD20 mRNA was present in tibialis 
anterior (TA), quadriceps (QA), and diaphragm (DIA) from 3-month-old C57BL 
mice (Fig. 6B). Since data on CD20 expression from whole muscle may be biased 
by the presence of non-muscular CD20-expressing cells (e.g., cir-culating B-cells), 
we confirmed these results by performing RT-PCR on single muscle fibers. We 
detected CD20 mRNA in single fibers isolated from TA, QA, and DIA of C57BL 
mice (Fig. 6C), thus verifying the expression of CD20 at the mRNA level from 
myoblasts to mature muscle fibers. Sequencing of RT-PCR products from spleen, 
whole muscle, and isolated muscle fibers confirmed the amplified cDNA as CD20 
(Fig. 6D). 
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Figure 6: RT-PCR analysis of CD20 expression. (A) The presented bands were 
obtained using F1–R1 primers targeting the 3’-UTR of CD20 mRNA. Amplification 
with F2–R2 primers targeting the ORF of CD20 mRNA produced identical results. 
(A) CD20 mRNA was successfully amplified from growing C2C12 myoblasts and 
C2C12-derived myotubes. (B) Analysis of whole muscles returned a CD20-specific 
band in TA, QA, and DIA from C57BL mice. (C) CD20 mRNA was also detected in 
isolated muscle fibers from the same muscles, providing evidence of a muscle-
specific expression. (D) Bands obtained after F1–R1 amplification from spleen, 
whole muscle, and isolated fibers were sequenced to confirm the identity of 
amplified product as CD20. RNA from C57BL spleen and 3T3 fibroblasts were 
used as positive and negative controls, respectively. GAPDH was used as a 
loading control. 
2.2 Localization of CD20 in muscle cells and fibers 
Using western blot analysis with a polyclonal anti-CD20 antibody, proteins with 
molecular weights corresponding to that of CD20 (33–37 kD) were identified in both 
growing C2C12 myoblasts and C2C12-derived myotubes (Fig. 7A). The same 
signal was obtained in TA, QA, and DIA whole muscles and single fibers (Fig. 7B 
and C), revealing the presence of CD20 protein in all assayed samples. We 
considered that our findings of CD20 in mature muscle fibers could be due to a 
fusion process involving circulating CD20+ cells in vivo. To address this crucial 
point, we performed WB analysis on muscles isolated from SCID mice, which com-
pletely lack any potentially contaminating CD20+ B-lymphocytes due to genetic 
depletion [217, 218]. Importantly, the polyclonal anti-CD20 antibody still stained a 
D 
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33- to 37-kD band in TA, QA, and DIA muscles from SCID mice (Fig. 7D). WB 
analysis using a monoclonal anti-CD20 anti-body confirmed these results in all 
tested muscle samples (Fig. 7E). CD20 protein expression was comparable in 
C57BL whole muscles and single fibers, as well as in TA, QA and DIA from SCID 
mice (data not shown). Notably, we failed to detect CD20 by WB in brain, kidney, 
and lung (Fig. 7F), indicating that this protein is not broadly expressed. Flow 
cytometry analysis revealed up to 80% CD20+ C2C12 myoblasts with both 
polyclonal (Fig. 8A) and monoclonal (Fig. 8B) anti-CD20 antibodies, confirming the 
expression of CD20 protein and suggesting its membrane localization. To 
investigate the spatial localization of CD20, immunofluorescence analyses were 
performed on C2C12 myoblasts/myotubes and cryosections from C57BL and SCID 
muscles. In cultured C2C12 myoblasts/myotubes, CD20 staining showed a spotted 
pattern surrounding the entire cell body, typical of surface antigens when detected 
in culture. Additionally, CD20 nearly co-localized with laminin, suggesting its 
membrane localization on cultured muscle cells [227] (Fig. 8C and D). The 
membrane localization of CD20 was also observed in adult muscle fibers from 
C57BL mice, where the signal returned by the monoclonal anti-CD20 antibody co-
localized with the transmembrane protein α-sarcoglycan (Fig. 8E). Moreover, IF 
experiments confirmed the expression and the membrane localization of CD20 in 
TA and QA muscles isolated from immune-deficient SCID mice (Fig. 8F). IF 
observations were supported by WB analyses on isolated sarcolemma from C57BL 
TA, QA, and DIA, which confirmed CD20 expression at the membrane level in adult 
muscle fibers (Fig. 7G). Pre-exposure of anti-CD20 antibody to a specific blocking 
peptide resulted in a significant reduction of signal on a positive source of CD20 
(C57BL spleen), as well as on C2C12 myoblasts, verifying the antibody’s ability to 
bind its specific target (data not shown). Together, these data demonstrated the 
expression of CD20 protein in muscle, and excluded the possibility that this result 
was an artifact due to contaminating circulating CD20+ cells. 
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Figure 7: Western blot analysis of CD20 expression. (A–C) Immunoblotting 
experiments using the anti-CD20 (M-20) antibody confirmed the presence of CD20 
at the protein level in C2C12 myoblasts/myotubes, as well as in C57BL TA, QA, 
and DIA whole muscles and single fibers. (D) A CD20 band was also obtained with 
the same antibody in whole muscles isolated from B cell-depleted SCID mice, 
confirming that the CD20 expression was truly from muscle cells. (E) WB data were 
confirmed using a monoclonal antibody directed against the C-terminal region of 
CD20 in C57BL (in toto and as single fibers) and SCID (in toto) muscles. (F) WB 
analyses were performed on brain, kidney, and lung from C57BL mice using the 
anti-CD20 (M-20) antibody, revealing that CD20 was not broadly expressed in all 
tissues. (G) Membrane localization of CD20 was assessed by performing WB with 
anti-CD20 (M-20) antibody on isolated sarcolemma from C57BL TA, QA, and DIA 
muscles. 
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Figure 8: Analysis of CD20 localization. Flow cytometry analysis returned about 
80% CD20+ C2C12 myoblasts, using both a polyclonal (A) and a monoclonal (B) 
anti-CD20 antibody; cells stained with the appropriate isotype control (goat and 
rabbit IgG, respectively), were assayed as controls. Immunofluorescence staining 
was performed to evaluate the spatial localization of CD20 in C2C12 
myoblasts/myotubes and adult muscle fibers. The anti-CD20 (M-20) antibody 
showed a spotted pattern surrounding the entire cell body and nearly co-localizing 
with laminin, suggesting the membrane localization of CD20 in myoblasts (C) and 
myotubes (D). Muscle fibers expressing CD20 at the sarcolemma were detected 
using the anti-CD20 (C-term) monoclonal antibody in TA and QA muscles from 
C57BL (E) and SCID mice (F). The signal referring to CD20 co-localized with the 
transmembrane protein α-sarcoglycan. Images labeled as merge show the 
combination of all stained elements (CD20, laminin/ α-sarcoglycan, and nuclei). 
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2.3 Identification of CD20 by mass spectrometry 
To substantiate these findings, mass spectrometry (MS) was used to identify CD20 
in skeletal muscle cells and tissue. CD20 immunoprecipitates were prepared from 
C2C12 myoblasts and QA muscles from C57BL or SCID mice, resolved by SDS-
PAGE, and blotted with an anti-CD20 antibody. Stained bands that were also 
appreciable in silver-stained paired lanes from the same gel were recovered and 
processed for MS analysis, following in situ diges-tion and peptide extraction. 
CD20-derived peptides were detected in two bands from C2C12 myoblasts and 
three bands from C57BL and SCID QA (Fig. 9A), suggesting the presence of 
multiple CD20 isoforms in all analyzed samples. Approximately 50% amino acid 
sequence coverage was obtained (Fig. 9B) and the identified pep-tides returned a 
100% alignment match, exclusively with CD20 (data not shown), confirming its 
expression in C2C12 myoblasts and adult muscle. 
 
 
Figure 9: Mass spectrometry. (A) Using the anti-CD20 (M-20) antibody, CD20 
complexes were immunoprecipitated from C2C12 myoblasts, C57BL QA, and 
SCID QA, and resolved by SDS-PAGE. IP samples were split on multiple lanes of 
the same gel, some dedicated to WB and the others to silver staining. Bands 
stained with the anti-CD20 (M-20) antibody were identified and recovered from the 
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silver-stained lanes for MS analysis. Two bands from myoblasts and three bands 
from C57BL and SCID QA were analyzed. (B) The in-gel tryptic digest was 
extracted with 30 µl of 0.1% TFA:CH3CN (1:1), and the peptide mixture was 
subjected to MALDI-TOF analysis, operating in positive reflector mode with a 
matrix of  α-ciano-4-hydroxy-cinnamic acid. Identified peptides were representative 
of 46.7% of the CD20 primary sequence. 
2.4 C2C12 proliferation and viability are not affected by anti-CD20 
antibody 
We next investigated the functional aspect of CD20 expression in skeletal muscle. 
In the context of B-lymphocytes, CD20 is usually related to cell-cycle progression 
and proliferation [228, 229]. Importantly, CD20 is tar-geted by clinical monoclonal 
antibodies that can deplete B cells in vivo via a Ca2+-related apoptotic pathway 
[230-234]. To assess whether CD20 exerted similar functions in skeletal muscle, 
we assayed cell proliferation and apoptotic death on C2C12 myoblasts after 
exposure to anti-CD20 antibody. The MTT assay revealed no differences in 
proliferation behavior between untreated C2C12 myoblasts (OD ± SEM, 0.984 ± 
0.063) and those treated for 2h with anti-CD20 antibody (4  µg/ml: 1.005 ± 0.024; 
20  µg/ml: 0.952 ± 0.015) (Fig. 10A). Overnight treatment returned similar results 
(untreated 1.517 ± 0.061; 4  µg/ml: 1.342 ± 0.133; 20  µg/ml: 1.283 ± 0.060) (Fig. 
10A). Similarly, flow cytometry analysis of Annexin V/propidium iodide (PI)-stained 
cells did not show any induction of apoptosis in C2C12 myoblasts after treatment 
with anti-CD20 antibody, either after 2h (% AnnexinV+PI+ ± SEM, 0.27 ± 0.09% vs. 
untreated 2h: 0.36 ± 0.09%) or overnight antibody exposure (0.4 ± 0.1% vs. 
untreated ON: 0.47 ± 0.09%) (Fig. 10B). These data describe a lack of coupling 
between anti-CD20 treatment and proliferative/apoptotic pathways, indicating that 
the function of CD20 in C2C12 myoblasts differs from that previously reported for 
CD20 in B-cells. 
 
 
Figure 10: Evaluation of cell proliferation and viability after CD20 antibody 
targeting. (A) The MTT assay revealed no differences in proliferation rates among 
C2C12 myoblasts that were exposed or not to the anti-CD20 (I-20) antibody, 
regardless of antibody concentration (4 or 20 µg/ml) or treatment duration (2h or 
overnight) (n = 3 for each condition). (B) Analysis of Annexin V-PI-stained C2C12 
myoblasts showed that exposure to the anti-CD20 (I-20) antibody (4  µg/ml) had no 
effects on apoptotic cell death, either after 2h or overnight treatment (n = 6 for each 
condition).  
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2.5 Stable CD20 silencing in C2C12 myoblasts 
To expand the approaches aimed to investigate CD20 functionality in skeletal 
muscle, we stably knock down CD20 expression in C2C12 myoblasts. Cells were 
exposed to lentiviral particles delivering constructs that encode shRNA designed to 
target CD20 mRNA. Knock-down efficiency was assayed after selection of infected 
cells by RT-PCR and WB, revealing 70% knock down of CD20 gene expression 
(Fig. 11A) and 60% silencing at the protein level (Fig. 11B). 
 
 
 
Figure 11: Evaluation of CD20 silencing. (A and B) CD20 expression knock 
down was monitored by semi-quantitative RT-PCR and WB, after puromycin 
selection of infected cells. The F1–R1 primers (aligning in the 3’-UTR of CD20 
mRNA) and the anti-CD20 (M20) antibody were used. C57BL spleen was assayed 
as a positive control, and GAPDH was used as a loading control. 
2.6 CD20 targeting affects store-operated Ca2+ entry in C2C12 
myoblasts  
To further investigate the function of CD20 expression in skeletal muscle, we 
explored its involvement in the control of intracellular Ca2+ dynamics. Several 
previous reports have suggested that CD20 may regulate Ca2+ influx by modulating 
or acting directly as a SOC channel [136, 137, 225, 235, 236]. Accordingly, we 
assessed whether CD20 targeting modulates the magnitude of SOCE in C2C12 
myoblasts. After loading with Fura-2, cells displayed a homogeneous staining 
without dye accumulation into intracellular compartments (Fig. 12A). Real-time 
fluorescence recording was performed at resting conditions, then during the store-
depletion step and throughout the increase of external Ca2+ concentration, such 
that both the preparative (store depletion) and effective (Ca2+ re-entry) phases of 
SOCE were monitored. After addition of extra-cellular Ca2+, the 340/380 nm ratio 
showed a significantly lower increase in anti-CD20 treated myoblasts (n = 42) (Fig. 
12C), indicating that Ca2+ re-entry induced by store-depletion was impaired in this 
condition (∆340/380 ± SEM, untreated: 0.053 ± 0.003; anti-CD20: 0.025 ± 0.003; P 
A 
B 
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< 0.001) (Fig. 12G). Cells receiving control antibody (anti-FLAG; n = 32) (Fig. 12D) 
behaved identically to untreated cells (n = 41) (Fig. 12B), supporting the specificity 
of our observations (∆340/380 ± SEM, untreated: 0.053 ± 0.003; anti-FLAG: 0.058 
± 0.003; P > 0.05) (Fig. 12G). Measurements of SOCE were also performed on 
CD20-silenced C2C12 myoblasts. Consistently to what observed after anti-CD20 
treatment, SOCE was markedly reduced in CD20-silenced C2C12 myoblasts (n = 
43) (Fig. 12E), as indicated by the lower increase in the 340/380 nm ratio 
measured after extracellular Ca2+ raising (∆340/380 ± SEM, untreated: 0.053 ± 
0.003; RNAi CD20: 0.020 ± 0.001; P < 0.001) (Fig. 12G). On the contrary, in cells 
infected with an shRNA encoding a scrambled sequence (n = 20) (Fig. 12F) the 
340/380 nm ratio showed an increase comparable to that of untreated cells 
(∆340/380 ± SEM, untreated: 0.053 ± 0.003; RNAi scrambled: 0.066 ± 0.005; P > 
0.05) (Fig. 12G). Importantly, similar ∆340/380 nm ratios were observed in 
response to thapsigargin in all the conditions tested, ruling out the possibility that 
the impairment of SOCE observed after CD20-targeting was related to a lower 
depletion efficacy (∆340/380 ± SEM, untreated: 0.053 ± 0.002; anti-CD20: 0.049 ± 
0.002; anti-FLAG: 0.052 ± 0.004; RNAi CD20: 0.061 ± 0.006; RNAi scrambled: 
0.047 ± 0.004; P > 0.05) (Fig. 12H). Similarly, the levels of intracellular Ca2+ 
recorded at rest were homogeneous among all the experimental conditions 
analyzed, with the exception of anti-CD20 treated cells showing a significantly 
higher concentration (data not shown). To assess whether CD20 targeting 
specifically modulated SOCE, cells were assayed in the presence of the SOC influx 
inhibitor BTP2. No differences were observed in ∆340/380 nm ratio when 
comparing anti-CD20- treated (n = 21) or CD20-silenced C2C12 myoblasts (n = 22) 
to cells receiving the SOCE blocker alone (n = 20), suggesting that CD20 targeting 
was ineffective if SOCE could not occur (∆340/380 ± SEM, BTP2: 0.012 ± 0.001; 
BTP2 + anti-CD20: 0.012 ± 0.001; BTP2 + RNAi CD20: 0.013 ± 0.001; P > 0.05) 
(Fig. 12I). 
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Figure 12: SOCE measurements on CD20-targeted C2C12 myoblasts. (A) Ca2+ 
measurements were performed on cells displaying an homogeneous staining after 
loading with Fura-2-AM, thus avoiding biases due to dye accumulation into 
intracellular compartments. (B–F) Representative traces of the 340/380 nm 
excitation ratio are shown for each experimental condition assayed. Fluorescence 
was real-time recorded starting at rest, then during the store-depletion step with 
thapsigargin and throughout the addition of extracellular Ca2+. (G) SOCE changes 
were quantified as _340/380 nm excitation ratio after addition of 2 mM extracellular 
Ca2+. SOCE was significantly impaired after exposure to the anti-CD20 (I-20) 
antibody or CD20-gene silencing. Cells receiving control antibody (anti-FLAG) or 
scrambled shRNA did not showed significant differences in SOCE magnitude in 
comparison to untreated cells. ***P < 0.001, referring to Bonferroni’s multiple 
comparison post-test outcome vs. untreated group. (H) C2C12 myoblasts showed 
a comparable response to thapsigargin in all the conditions tested, indicating that 
store-depletion occurred with analogous efficiency. (I) CD20 antibody (I-20) 
targeting or gene silencing was ineffective when the specific SOC influx inhibitor 
BTP2 was used, giving evidence that SOCE was specifically affected by CD20-
targeting. 
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2.7 Expression of CD20 in human myoblasts and skeletal muscle 
tissue  
Finally, we assessed CD20 expression in human muscle cells and tissue. Human 
CD20 mRNA was amplified from CHQ cells, a line of human skeletal myoblasts, as 
well as from adult muscular tissue (Fig. 13A). A band in the molecular range of 33–
37 kD was stained by the anti-CD20 (M-20) antibody, revealing CD20 expression 
at the protein level (Fig. 13B). This observation was supported by MS analysis, with 
10 CD20-derived peptides identified in IP from adult human muscle (Fig. 13C). 
 
 
Figure 13: Expression of CD20 in human skeletal muscle. (A) CD20 mRNA 
was successfully amplified from human myoblasts and muscular tissue. (B) The 
anti-CD20 (M-20) antibody stained a band in the molecular range of 33–37 kD, 
suggesting CD20 expression at the protein level in human muscular cells and 
tissue. (C) The presence of CD20 protein was confirmed by MS analysis, allowing 
identification of 10 CD20- derived peptides in IP from adult muscular tissue. The 
anti-CD20 (M-20) antibody was used to perform IP. 
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DISCUSSION 
Being involved in the control of cell growth, differentiation, metabolism, and gene 
expression, the calcium ion plays an essential role in the physiology of all living 
cells. Accordingly, multiple mechanisms contribute to the precise control of its 
intracellular concentration ([Ca2+]i) [70, 71, 237]. Particularly in skeletal muscle, the 
efficient regulation of cytosolic Ca2+ is crucial for tissue functionality [95]. Indeed, 
impairment of Ca2+ homeostasis has been shown to contribute to the etiology of 
muscle fiber injury, especially in some muscular disorders such as Duchenne 
muscular dystrophy (DMD) [179, 180, 238-240]. DMD is a progressive 
neuromuscular disease characterized by lack of dystrophin, a 427kD protein 
expressed at the inner face of the sarcolemma [175, 241]. The absence of 
dystrophin has two main consequences: (a) the cell membrane is more fragile and 
can be damaged during eccentric muscle contraction; (b) membrane proteins, 
especially ion channels, are deregulated. Strong perturbations of calcium handling 
were observed in DMD muscle fibers [179, 180, 239]. Moreover, studies performed 
on dystrophic muscle cells from mdx mice, the animal model of DMD [174], have 
suggested that a persistent intake of Ca2+ activates Ca-sensitive proteolytic and 
phospholipolytic activities [238, 240] resulting in the degradation of dystrophic 
muscle tissue. Alterations of the sodium permeability were not observed in DMD or 
mdx myoblasts, ruling out a general (nonspecific) increase of ionic permeability 
through membrane wounds and supporting the involvement of specific 
transmembrane channels and intracellular pathways. In particular, the store 
operated calcium channels (SOCCs) seem to be involved in the entries of Ca2+ in 
the dystrophic muscle fibers [86]. Although the impairment of Ca2+ homeostasis 
affecting dystrophic muscular cells has been extensively reported, the conditions of 
calcium-release and the role of SOCCs in dystrophic myogenic progenitors were 
not investigated before. To start addressing this issue, we firstly characterized the 
immunophenotype of normal and dystrophic blood-derived CD133+ progenitors, 
whose myogenic potential was previously demonstrated [50, 220]. Unexpectedly, 
expression of the membrane antigen CD20 was detected. Knowledge about the 
biology of CD20 is relatively scarce, and its precise functionality is still not 
understood. However, evidences of its involvement in calcium homeostasis are 
growing. Cell lines transfected with CD20 show an increased calcium conductance 
across the plasma membrane, strongly suggesting that CD20 functions as an 
important channel for regulating calcium homeostasis [136, 137]. Furthermore, 
reduced CD20 expression in B cell lines result in significantly decreased calcium 
entry across the plasma membrane [137, 138]. Finally, some insight has been 
provided by studies showing that CD20 can associate with lipid raft domains of the 
plasma membrane, where it is probably involved in store-operated Ca2+ entry 
(SOCE) (Deans et al., 1998; Li et al., 2004). Together with these findings, 
supporting a direct role of CD20 in the regulation of transmembrane conductive 
Ca2+ flux, a CD20-related pathway able to modulate intracellular Ca2+ was also 
described. Indeed, CD20 was shown to be a component of a multimolecular 
complex including the src-family tyrosine kinases Lyn, Fyn and Lck, together with a 
75/80 kD protein phosphorylated on tyrosine residues in vivo [224]. CD20-
associated p75/80 has been identified as PAG, an ubiquitous, highly tyrosine-
phosphorylated adaptor protein localized exclusively to lipid rafts [242, 243]. Also 
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known as Csk-binding protein (Cbp), PAG recruits Csk to lipid rafts to maintain 
resident src-family tyrosine kinases in the inactive state. Changes in either the 
conformation of CD20 or its phosphorylation state, or both, could regulate its 
association with Lyn, Fyn and Lck, resulting in an activation of such kinases and 
initiating of downstream signaling [138, 224, 225]. The activation of Lyn, the src-
kinase accounted for most of the PTK activity in the CD20 complex [224], triggers a 
cascade of events leading to Ca2+ mobilization from intracellular stores after 
activation of PLCγ2 and PI3-K [226]. Quantitative measurements of [Ca2+]i revealed 
an higher percentage of dystrophic cells exceeding the reference value of 100 nM 
(p<0.001), giving evidence, for the first time, of an altered regulation of intracellular 
Ca2+ affecting dystrophic blood-derived CD133+ stem cells. Additionally, an higher 
percentage of CD133+CD20+ cells was detected in DMD than normal blood. To 
investigate the possible involvement of CD20 in the intracellular Ca2+ overload 
observed in dystrophic cells, experiments were performed to quantify its expression 
as well as to evaluate its phosphorylation. While the number of CD20 molecules on 
the membrane of normal and DMD blood-derived CD133+ stem cells was not 
significantly different, the greater threonine phosphorylation observed in dystrophic 
cells possibly reflected a more consistent activation of CD20-related signaling. 
These results sustained an involvement of CD20 in the Ca2+ impairment affecting 
dystrophic CD133+ stem cells, reasonably related to its signaling activity rather 
than to a different number of molecules expressed. Given the absence of 
physiological agonists, we started to look for a soluble, released factor potentially 
able to indirectly activate CD20. ELISA assays demonstrated an abnormal release 
of BDNF from dystrophic circulating CD133+ stem cells. We thus focused our 
attention on the molecular pathways undergoing activation after BDNF interaction 
with its receptor, TrkB. Presented results demonstrated a connection between 
BDNF/TrkB signaling and CD20 activation, since a strong induction of CD20 
phosphorylation was observed after cell exposure to BDNF. Reasonably, the heavy 
threonine-phosphorylation detected in un-stimulated DMD cells depended on the 
higher BDNF release described above. Moreover, we showed that BDNF-induced 
CD20 phosphorylation was not followed by the same events in normal and 
dystrophic cells. Although CD20-Lyn interaction was observed in both normal and 
dystrophic circulating CD133+ stem cells after BDNF treatment, only in DMD cells 
does the recruited src-kinase undergo phosphorylation. This was likely to promote 
the activation of additional intracellular pathways that, by acting in synergy with 
TrkB-related signaling, contribute to the modulation of intracellular Ca2+ levels. Our 
data described a situation where the same stimulus (BDNF) resulted in a different 
response in normal and dystrophic blood-derived CD133+ stem cells in term of 
intracellular Ca2+ rise, according to the activation of different signaling pathways. 
Indeed, while the exposure to BDNF of CD133+ stem cells isolated from normal 
blood will only result in the activation of TrkB signaling, in dystrophic cells the 
synergic activation of TrkB and CD20-Lyn pathways will take place, leading to a 
supplemental intracellular free calcium increase. These considerations were 
strongly supported by measurements of intracellular free Ca2+ in BDNF-stimulated 
normal and dystrophic circulating CD133+ stem cells, revealing a more consistent 
increase of [Ca2+]i in dystrophic cells, as expected. Together, these data 
demonstrated that the intracellular Ca2+ overload observed in DMD blood-derived 
CD133+ stem cells involved, at least, two mechanisms acting in synergy: 1) an 
increased BDNF release, leading to an autocrine/paracrine activation of TrkB 
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pathway; 2) the activation of CD20-Lyn signaling, resulting in a supplementary 
intracellular calcium increase. We speculated that the absence of dystrophin in 
DMD circulating CD133+ stem cells may affect membrane integrity, leading to an 
abnormal activation of CD20-related signaling. Interestingly, we described the 
absence of Dp71 protein in dystrophic circulating CD133+ stem cells. Several 
works reported a reduced and/or compromised expression of Dp71, the ubiquitous 
dystrophin isoform, in dystrophic tissues that, at least formally, cannot be explained 
considering the site of mutation on the DMD gene. Altered Dp71 transcripts were 
found in astrocytes of patients with severe cerebral dysfunction [244] and an 
impaired oligomerization of Dp71 has been demonstrated in Dp427-deficient mdx 
brain [245]. Furthermore, a reduced expression of Dp71 was observed in 
endothelial and glial cells derived from mdx fetuses, newborn and adult mice, 
associated with impaired blood-brain barrier (BBB) development [246]. Finally, 
association of Dp71 with the cell membrane was demonstrated [247], identified in 
the platelet membrane cytoskeleton [248], and a critical role for the clustered 
localization of potassium channels in retinal glial cells was described [249]. These 
data suggested that the absence of Dp71 in the DMD circulating CD133+ stem cells 
may account for the impairment of CD20-related signaling pathway, resulting in 
intracellular Ca2+ overload. However, further studies are needed to demonstrate 
the existence of a functional relationship between Dp71 and CD20, whether 
mediated by a CD20-Dp71 direct interaction or by an indirect link involving other 
dystrophin associated proteins. The rescue of dystrophin expression in engineered 
dystrophic circulating CD133+ stem cells provided the recovery of muscle force and 
endurance after engraftment into dystrophic animal models [220]. So far, we do not 
know whether the expression of Dp71 dystrophin isoform on the engineered 
dystrophic circulating CD133+ stem cells may also account for intracellular Ca2+ 
normalization. However, in dystrophin deficient cells where expression of full-length 
dystrophin was forced by plasmid microinjection, the development of calcium-
handling abnormalities was prevented by maintaining the resting [Ca2+]i at low 
levels and decreasing global calcium-release amplitudes [250]. Furthermore, mini-
dystrophin (which lacks 17 repeats of the central rod domain) retains the ability to 
negatively regulate store-dependent calcium influx and to restore a normal calcium 
homeostasis. The domains involved in the negative control of SOCCs may be 
situated in the C-terminal domain, a protein region present in all dystrophin 
isoforms, included Dp71, and where binding sites for dystrophin associated 
proteins can be found. Additional research focused on CD20-related signaling in 
blood-derived CD133+ stem cells may enhance the understanding of their 
differentiative behavior and, in so doing, may contribute to the development of 
experimental strategies for the treatment of DMD. In this context, toward which the 
main efforts of our lab are focused, the possible contribution of CD20 to the 
regulation of Ca2+ handling in skeletal muscle is an important point to address. 
Moreover, it should be taken into account that circulating CD133+ progenitors and 
committed muscular cells share common mesodermic origins, so that similar 
altered pathways could be found. Human muscle biopsies for research purposes 
are not easy to obtain, particularly from DMD patients. Accordingly, we started to 
evaluate whether CD20 is expressed and contributes to calcium handling in C2C12 
murine skeletal myoblasts cell line. Our findings unequivocally described CD20 
expression in C2C12 myoblasts/myotubes and mature muscle fibers, both at the 
mRNA and protein levels. RT-PCR, flow cytometry, WB, and IF data were 
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supported by MS analysis that identified 15 CD20-related peptides after 
immunoprecipitation from C2C12 myoblasts, C57BL QA, and SCID QA whole 
lysates. Data obtained from C57BL-isolated muscle fibers, together with 
observations in C2C12 myoblast pure populations, provided strong evidence 
supporting muscle-specific CD20 expression. Furthermore, CD20 detection in 
muscles isolated from B cell-depleted SCID mice confirmed the muscular origin of 
our findings, by excluding potential contamination and/or fusion with circulating 
CD20+ cells. Being detected at the membrane level in both myoblasts and mature 
fibers from different muscles, the observed muscular CD20 expression pattern 
differed from that in B cells, where CD20 is expressed in early B-cell precursors 
and mature B-cells but is lost with differentiation into plasma cells [251, 252]. 
Interestingly, IF analysis of C2C12 myoblasts/myotubes and of C57BL and SCID 
muscles revealed that CD20 was not widely expressed on all muscle cells and 
fibers. Functional experiments showed that proliferation and viability of C2C12 
myoblasts were not affected by anti-CD20 treatment, highlighting differences in 
comparison to previous descriptions of CD20 function in B cells. Discrepancies in 
term of expression time-course and/or functionality are quite common when 
comparing the behavior of a protein in two distinct environments. Differences may 
arise from protein expression level, presence/absence of tissue-specific binding 
partners, or from tissue-specific features. Although recent studies have made 
significant advancements in the field [117, 207, 213, 253], there are relatively few 
reports of SOCE activity in skeletal muscle, and the function/regulation of SOC 
channels in this tissue is not fully understood [130, 254, 255]. Previous studies 
have suggested CD20 involvement in regulating calcium homeostasis, possibly 
through a SOCE mechanism. The present data strongly implicate CD20 as a novel 
modulator of this pathway in C2C12 myoblasts. By using different targeting 
approaches, we showed that CD20 inhibition specifically impaired Ca2+ re-entry 
after store-depletion in C2C12 myoblasts. The observed reduction in Ca2+ re-entry 
magnitude after antibody binding or gene silencing, suggested a role for CD20 as a 
component of the SOCE machinery in these cells. Previous studies have 
demonstrated increased transmembrane Ca2+ conductance after transfection of 
CD20 cDNA [136, 137, 235, 256]. Since the exposure to thapsigargin displayed 
similar effects in untreated and CD20-targeted C2C12 myoblasts, the observed 
impairment of SOCE can reasonably be addressed to a specific impairment of Ca2+ 
re-entry, ruling out biases due to different starting points at the end of store-
depletion. Although in different cell types, the elevation of intracellular Ca2+ upon 
anti-CD20 antibody binding has been extensively reported before [234, 257-259]. 
Interestingly, also in C2C12 myoblasts a significantly higher intracellular Ca2+ 
concentration at rest was measured when CD20 inhibition was achieved through 
antibody binding. Since CD20-silenced C2C12 myoblasts displayed normal levels 
of resting Ca2+, we speculate that in these cells intracellular Ca2+ raising after CD20 
inhibition can be bypassed through an adaptive response, possibly leading to the 
expression or up-regulation of other proteins involved in Ca2+ homeostasis. Data 
presented provide novel insights into the expression pattern of CD20, confirming its 
membrane localization in skeletal muscle myoblasts and adult fibers. Analysis of 
SOCE in C2C12 myoblasts after CD20 targeting with specific antibody or gene 
silencing revealed a specific impairment of the observed phenomenon. It is not yet 
known whether CD20 modulates SOCE by acting alone or, more likely, through 
interaction with other proteins. Further work is needed to study the functional 
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impact of SOCE modulation through CD20 targeting in muscle cells and tissue, as 
well as to extend the present findings to human skeletal muscle. 
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CONCLUSIONS 
The calcium ion plays an essential role in the physiology of all living cells. 
Particularly in skeletal muscle, the efficient regulation of cytosolic Ca2+ is crucial for 
tissue functionality and impairment of Ca2+ homeostasis has been involved in  the 
etiology of Duchenne muscular dystrophy (DMD). Although the impairment of Ca2+ 
homeostasis affecting dystrophic muscular cells has been extensively reported, the 
pathways involved in calcium-release and the role of store-operated Ca2+ channels 
in dystrophic myogenic progenitors were not investigated before.  
 
The main findings reported in the first section of the thesis are summarized below: 
• Quantitative calcium measurements revealed an higher [Ca2+]i in dystrophic 
blood-derived CD133+ stem cells giving evidence, for the first time, of an altered 
Ca2+ regulation in dystrophic progenitors retaining myogenic potential.  
• CD20-related signaling is involved in the Ca2+ impairment observed in 
dystrophic CD133+ stem cells. 
• Connection between BDNF/TrkB signaling and CD20 activation was 
demonstrated, although this was not followed by the same molecular events in 
normal and dystrophic cells. 
• CD20-Lyn interaction was observed in both normal and dystrophic circulating 
CD133+ stem cells after BDNF treatment, but only in DMD cells does the 
recruited src-kinase undergo phosphorylation.  
• Measurements of intracellular free Ca2+ in BDNF-stimulated normal and 
dystrophic circulating CD133+ stem cells revealed more consistent increase of 
[Ca2+]i in dystrophic cells. 
 
Together, these data demonstrated that the intracellular Ca2+ overload observed in 
DMD blood-derived CD133+ stem cells involved, at least, two mechanisms acting in 
synergy: 1) an increased BDNF release, leading to an autocrine/paracrine 
activation of TrkB pathway; 2) the activation of CD20-Lyn signaling, resulting in a 
supplementary intracellular calcium increase. We speculated that the absence of 
dystrophin in DMD circulating CD133+ stem cells may affect membrane integrity, 
leading to an abnormal activation of CD20-related signaling. 
 
The main efforts of our lab are focused on the development of experimental 
strategies to ameliorate the phenotype of dystrophic patients. In this context, the 
possible contribution of CD20 to the regulation of Ca2+ handling in skeletal muscle 
is an important point to address, especially considering that circulating CD133+ 
progenitors and committed muscular cells share common mesodermic origins. 
Human muscle biopsies for research purposes are not easy to obtain, particularly 
from DMD patients. Accordingly, we started to evaluate whether CD20 is 
expressed and contributes to calcium handling in C2C12 murine skeletal myoblasts 
cell line. Interestingly, several studies demonstrated the association of CD20 with 
lipid raft domains of the plasma membrane, where it probably functions as a store-
operated Ca2+ channel. Recent works indicated that store-operated Ca2+ entry 
(SOCE) plays a central role in skeletal muscle physiology and development, but 
there remain a number of unresolved issues relating to SOCE modulation in this 
tissue. 
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The main findings reported in the second section of the thesis are summarized 
below: 
• CD20 is expressed at the membrane of C2C12 myoblasts/myotubes and 
mature muscle fibers, both at the mRNA and protein levels.  
• Functional experiments showed that proliferation and viability of C2C12 
myoblasts were not affected by anti-CD20 treatment. 
• CD20 inhibition specifically impaired Ca2+ re-entry after store-depletion in 
C2C12 myoblasts, suggesting a role for CD20 as a component of the SOCE 
machinery in these cells. 
 
FUTURE PERSPECTIVES 
- To investigate the existence of a functional relation between Dp71 and CD20, 
possibly mediated by a direct interaction or by an indirect link involving other 
dystrophin associated proteins.  
 
- To understand whether CD20-related signaling affects the differentiative potential 
of normal and dystrophic blood-derived CD133+ stem cells, both in vitro and in vivo. 
 
- To improve the characterization of CD20 expression in skeletal muscle. Given 
that CD20 was not widely expressed on all muscle fibres, the correlation with 
different myosin isoforms is an intringuingly point to address in order to highlight 
the contribute of CD20 to muscular specific features.     
 
- To study the functional impact of SOCE modulation through CD20 in muscle cells 
and tissue, starting from myoblasts differentiation after CD20 targeting. 
 
- To understand whether CD20 modulates SOCE by acting alone or, more likely, 
through interaction with other proteins. Accordingly, a functional interaction with the 
main actors of SOCE (ORAI1 and STIM1) should be investigated.  
 
- To extend the findings concerning CD20 to dystrophic and human skeletal muscle 
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